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A. List of abbreviations 
Less frequently used abbreviation are defined upon their first use in the text. 
ACC  acetyl-CoA carboxylase  
AMP  adenosine monophosphate 
APOB  apolipoprotein B 
ATP  adenosine triphosphate 
BMI  Body Mass Index 
DAG  diacylglycerol 
ERK  extracellular signal-regulated kinase 
FAS  fatty acid synthase 
FoxO1  forkhead box O1  
G6Pase glucose-6-phosphatase  
GSK3β glycogen synthase kinase 3β  
GTP  guanosine-5'-triphosphate 
IKKβ  inhibitor of nuclear factor ĸB kinase β 
INSR  insulin receptor 
IRS1/2  insulin receptor substrate 1/2 
JNK  c-Jun N-terminal protein kinase 
MAPK  mitogen-activated protein kinase  
mTORC1 mammalian target of rapamycin complex 1 
mTORC2 mammalian target of rapamycin complex 2 
NAFLD non-alcoholic fatty liver disease 
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PEPCK phosphoenolpyruvate carboxykinase 1 
PGC1α peroxisome proliferator-activated receptor gamma, coactivator 1α 
PH  pleckstrin homology 
PI3K  phosphatidylinositol 3-kinases 
PIP2  phosphatidylinositol-4,5-bisphosphate 
PIP3  phosphatidylinositol-3,4,5-triphosphat 
Pkbβ-/-  Pkbβ-deficiency 
PKB  protein kinase B/AKT 
PKC  protein kinase C 
PP2A  protein phosphatase 2A 
PPARγ  peroxisome proliferator-activated receptor g 
PTEN  phosphatase and tensin homolog 
Pten+/-  Pten-haplodeficiency 
PTP1b  protein tyrosine phosphatase, non-receptor type 1 
Raptor  regulatory associated protein of MTOR, complex 1 
Rheb  Ras homolog enriched in brain 
Rictor  RAPTOR independent companion of MTOR, complex 2 
S6K  ribosomal S6 kinase 
SREBP1-c sterol regulatory element binding transcription factor 1 
T2D  type 2 diabetes mellitus  
TSC1/2 tuberous sclerosis complex 1/2 
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B. Summary 
Non-alcoholic fatty liver disease (NAFLD) is a major health problem and occurs frequently in 
the context of obesity and type 2 diabetes mellitus (T2D). Insulin resistance of the liver and/or 
peripheral tissues is considered to drive ectopic lipid accumulation in hepatocytes, but individual 
contributions are not fully understood. Hepatocyte-specific Pten-deficiency in mice was shown 
previously to result in hepatic steatosis due to hyperactivated PKBβ in the liver. However, the 
role of peripheral insulin sensitive tissues on PTEN/PKBβ-dependent development of NAFLD 
has not been addressed.  
 
The aim of this thesis is to characterize the effects of systemically perturbed PTEN/PKBβ 
signaling on hepatic lipid content using Pten-haplodeficient (Pten+/-/Pkbβ+/+) mice and Pten-
haplodeficient mice lacking Pkbβ (Pten+/-/Pkbβ-/-). We found that Pten+/-/Pkbβ+/+ mice have a 
more than 2-fold reduction in hepatic lipid content compared to control mice, similar to the low 
level observed in Pten+/-/Pkbβ-/- mice. Pten+/-/Pkbβ+/+ mice showed enhanced insulin signaling in 
the liver indicating that extra-hepatic factors prevent hepatic lipid accumulation. Further results 
suggested that augmented PKBβ activity in the skeletal muscle of Pten+/-/Pkbβ+/+ mice might 
reduce hepatic lipid content. Indeed, skeletal muscle-specific expression of constitutively active 
PKBβ reduced hepatic lipids in Pten+/+Pkbβ+/+ mice and dominant negative PKBβ increased 
hepatic lipid content in both Pten+/+Pkbβ+/+ and Pten+/-/Pkbβ+/+ mice.  
 
The results obtained during this study show that PKBβ activity in skeletal muscle regulates lipid 
accumulation in the livers of Pten+/+Pkbβ+/+ and Pten+/-/Pkbβ+/+ mice, and emphasizes the role of 
skeletal muscle in the pathophysiology of NAFLD.  
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1. Introduction 
1.1. Global burden of obesity and diabetes 
Obesity has now reached epidemic dimensions worldwide. The World Health Organization 
(WHO) estimates that there were 1.4 billion overweight (BMI = 25 – 29.9 kg/m2) and 500 
million obese (BMI ≥ 30 kg/m2) people in the world in 2008 (Figure 1) (1). A study from 2005 
projected that in 2030 there will be 2.2 billion overweight and 1.1 billion obese people (2). Even 
though recent data from the Organisation for Economic Co-operation and Development revealed 
that the rates of obesity is increasing less than previously projected and even remain stable in 
some countries, obesity will persist as a global burden in the future (3).  
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Global prevalence of obesity. The map is showing the global prevalence of obesity in 
people above an age of 20 years from both sexes in 2008. Image adapted from (4). 
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The increasing rates of overweight and obesity in children with a prevalence of 25% or higher in 
many countries are even more alarming (5, 6). Obese children may develop diseases such as 
cardiovascular disease and type 2 diabetes mellitus (T2D) and have increased risk of adult 
morbidity and premature mortality (5-7).  
 
Obesity is the most common cause of insulin resistance and is the major risk factor for T2D (8, 
9). Thus, the rising incidence of obesity is paralleled by an increasing number of insulin resistant 
and diabetic patients. It is estimated that there will be 439 million people with T2D in 2030 (10). 
Systemic inflammation and ectopic accumulation of lipids in cells are considered to drive insulin 
resistance in the context of obesity (8, 9, 11).  The molecular mechanisms linking inflammation 
and intracellular lipids to insulin resistance are described in section 1.3.2. Mechanisms of 
obesity-induced / acquired insulin resistance.    
 
The clustering of obesity, insulin resistance and/or related comorbidities, such as hyperlipidemia, 
glucose intolerance and hypertension, increases the risk of developing cardiovascular disease and 
T2D and is known as the metabolic syndrome (12). It is now widely accepted that non-alcoholic 
fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome (13). 
 
1.2. Non-alcoholic fatty liver disease 
1.2.1. NAFLD is a major health problem 
NAFLD affects 30% of adults and 10% of children in the general population of developed 
countries (14-16). Importantly, NAFLD frequently occurs in the context of obesity, insulin 
resistance and T2D. Approximately 75% of obese and diabetic patients and 95% of morbid obese 
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(BMI ≥ 35 kg/m2) patients develop NAFLD (17, 18). Given the high incidence of obesity and 
T2D, NAFLD is now the most common liver disease worldwide (19).   
 
The term NAFLD defines the presence of hepatic steatosis in the absence of significant alcohol 
consumption and other liver diseases (20, 21). Traditionally, the term NAFLD has been used for 
a disease continuum from simple steatosis to steatohepatitis and fibrosis, but it was proposed to 
distinguish between simple steatosis (NAFLD) and more severe liver injuries (e.g. non-alcoholic 
steatohepatitis, NASH) (17). Hepatic steatosis is characterized by accumulation of predominantly 
macrovesicular lipid droplets in the cytoplasm of more than 5% of hepatocytes (20, 21). In early 
stages lipid droplets are typically clustered in acinar zone 3 and, in later stages, may occupy the 
whole acinus (Figure 2 A, B) (19, 22).  
 
 
 
 
 
 
 
 
It is estimated that ~20% of obese patients with hepatic steatosis develop necro-inflammatory 
changes in the liver termed as NASH (13, 21). NASH may progress to fibrosis and cirrhosis and 
eventually to hepatic failure and hepatocellular carcinoma (13, 21, 23). As not all cases of 
NAFLD progress to NASH a “2nd hit” may be required to induce the progression of NAFLD. 
Today it is considered that a combination of multiple factors, such as genetic predisposition, 
Figure 2. Appearance of 
hepatic steatosis. Histological 
sections show normal liver 
morphology (A) and 
accumulation of macro-
vesicular lipid droplets in 
hepatocytes (B). PT, portal 
triad; CV, central vein. Image 
adapted from (23) 
A 
B 
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oxidative and endoplasmatic reticulum (ER) stress, hepatocyte death and higher susceptibility to 
liver damage by other means may trigger the progression of NAFLD to NASH (23-28). 
However, the individual contribution of these factors on disease progression remains 
controversial and is likely to differ from patient to patient. NASH may also not always be 
preceded by NAFLD (Figure 3) (17, 23). While in the past NAFLD was thought to be benign, it 
is now clear that it is a major health problem and, due to its forms of progression, it is about to 
become one of the primary indications for liver transplantation (23, 29). 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Figure 3. Progression of 
NAFLD to NASH. (A, B) 
Histological sections 
showing inflammatory 
changes in steatotic liver 
(A) and blue-stained 
fribrotic fibers in cirrhotic 
liver (B). (C) Schematic 
illustration of the 
progression from NAFLD 
to end stage liver diseases. 
PT, portal triad; CV, 
central vein.  Images 
adapted from (23). 
A 
B 
C 
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1.2.2. Development of NAFLD in the context of obesity and insulin resistance 
The association of NAFLD with obesity and insulin resistance is well known, but the underlying 
mechanisms driving ectopic accumulation of lipids in hepatocytes are not fully understood.  
 
In 2005, Donelly and colleagues characterized the relative contribution of different sources on 
hepatic lipid content in obese patients using a multi-stable-isotope approach (23, 29). This study 
revealed that in obese patients approximately 60% of lipids in the liver are derived from serum 
nonesterfied fatty acid (NEFA) pool, 25% originate from de novo lipogenesis in the liver and 
15% are derived directly from dietary intake (23, 29). Given the high contribution of serum 
NEFA pool to hepatic lipid content and that the inhibitory effect of insulin on adipose tissue 
lipolysis is likely to be impaired in patients with NALFD, Donelly and colleagues concluded that 
adipose fatty acid flux is probably the major contributor to the development of NAFLD (29).  
 
Several studies suggest that insulin resistance of skeletal muscle has a central role in the 
development of NAFLD. In these studies the metabolic fate of ingested carbohydrates was 
analyzed by protium (1H) and carbon-13 (13C) magnetic resonance spectroscopy in insulin 
resistant subjects (30, 31). The skeletal muscle glycogen synthesis in young, lean and insulin 
resistant subjects was reduced by approximately 60%, but hepatic de novo lipogenesis and 
triglyceride content were increased by more than 2-fold compared to insulin sensitive control 
subjects (30). Similar results were also seen in insulin resistant, elderly subjects (31). These 
studies indicate that muscle insulin resistance precedes hepatic insulin resistance and results in a 
redistribution of ingested carbohydrates from skeletal muscle glycogen synthesis towards hepatic 
de novo lipogenesis (30, 31). Importantly, hepatic de novo lipogenesis and lipid content were 
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found to be reduced by more than 30% after insulin sensitivity of skeletal muscle was improved 
by physical exercise in insulin resistant subjects (Figure 4) (32). Physical exercise improves 
insulin sensitivity and reduces hepatic lipid content also in obese and diabetic patients (33, 34). 
Thus, skeletal muscle insulin resistance could have a central role in NAFLD development and 
might be an effective therapeutic target (30-32).  
  
Selective resistance of the hepatic insulin signaling could also contribute to ectopic accumulation 
of lipids in the liver (35, 36). According to this, insulin fails to inhibit gluconeogenesis but still 
induces de novo lipogenesis in hepatocytes (35). Insulin levels remain elevated due to steady 
output of glucose from the liver, which further boosts hepatic de novo lipogenesis and 
accumulation of lipids (Figure 5) (35). This concept is supported by the characterization of lipid 
metabolism in insulin resistant patients with primary defects in the insulin receptor (INSR) or 
with defects in the downstream protein kinase PKBβ/AKT2 (23, 36). While patients with defects 
in INSR have low hepatic lipid content and moderate rates of de novo lipogenesis, patients with 
defects in PKBβ display increased hepatic lipid content and the rate of de novo lipogenesis was 
increased by approximately 3-fold (36). However, the number of patients in this study is limited 
and the contribution of selective hepatic insulin resistance on NALFD development in obesity 
and acquired insulin resistance remains to be elucidated.  
Figure 4. The effects of skeletal muscle 
insulin response on the fate of glucose. 
Skeletal muscle insulin resistance leads to 
redistribution of ingested glucose from 
glycogen synthesis in skeletal muscle towards 
hepatic de novo lipogenesis and increases 
hepatic lipid content. This can be inhibited by 
physical exercise. Image adapted from (23, 
32). 
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While selective hepatic insulin resistance could contribute to NAFLD development, it is still a 
matter of debate whether accumulation of lipids in hepatocytes causes hepatic insulin resistance. 
Several studies in humans demonstrate a tight association between hepatic lipid content and 
insulin sensitivity. Patients with severe lipodysthrophy develop NAFLD and hepatic insulin 
resistance (37, 38). Treatment of these patients in with recombinant leptin resolves hepatic 
steatosis, which is accompanied by improved insulin sensitivity (37, 38). Diabetic patients that 
were placed on a hypocaloric diet displayed a marked reduction of hepatic lipid content and 
improved insulin sensitivity, despite the absence of changes in intramyocellular lipid content and 
peripheral glucose uptake (38, 39). Thus, it was concluded that accumulation of lipids in 
hepatocytes causes (hepatic) insulin resistance (38). However in a recent review, Cohen listed a 
number of studies in humans and mice with monogenetic defects that develop NAFLD without 
insulin resistance (23). For instance patients with mutations in APOB gene that impairs export of 
hepatic triglycerides in the form of very low density lipoprotein (VLDL) have elevated hepatic 
lipid content, but have insulin sensitivity similar to controls (23, 40). Mice with impaired lipid 
mobilization in the liver by knockdown of abhydrolase domain containing protein 5 (CGI-58) in 
the liver and adipose tissue have severe hepatic steatosis, but display improved glucose tolerance 
Figure 5. Model of selective insulin 
resistance in the liver. It is proposed 
that postreceptor insulin resistance 
affects only distinct processes such as 
gluconeogenesis but not de novo 
lipogensis. This could lead increased 
hepatic lipid content. Image adapted from  
(36). 
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and insulin sensitivity (23, 41). Moreover, Cohen points out that accumulation of specific lipid 
species such as diacylglycerol (DAG) and ceramides that are known to cause insulin resistance 
do not necessarily lead to insulin resistance in the liver of mice with hepatic steatosis (23). Thus, 
Cohen concluded that mere lipid accumulation in the liver is not the cause of hepatic insulin 
resistance (23). Most likely additional factors such as specific subcellular localization and 
composition of lipid species are required that increased lipid content in hepatocytes interferes 
with insulin action (23).   
 
The proposed mechanisms driving lipid accumulation in the liver, the above-mentioned surplus 
in dietary energy intake, aberrant energy disposal due to peripheral and hepatic insulin resistance 
as well as elevated glucose and insulin level, are closely related and commonly coexist in obese 
and diabetic patients. Thus, it is likely that the development of NAFLD in the context of obesity 
and insulin resistance is a result of the combined action of these mechanisms (Figure 6).   
 
 
 
 
 
 
 
 
 
 
Figure 6. NAFLD development in 
the context of obesity and insulin 
resistance. A schematic overview is 
shown on how aberrant glucose 
disposal, selective insulin resistance 
and adipose tissue lipolysis contribute 
to NAFLD development during fed 
and fasted conditions in diabetic 
patients. CHO, carbohydrate; FA, 
fatty acids; IMCL, intramyocellular 
lipids; T2D, type 2 diabetes mellitus, 
TG, triglycerides.  Image adapted 
from (38). 
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Unraveling the relative contribution of these mechanisms in NAFLD and characterizing the 
effects of (therapeutic) intervention on hepatic lipid content and whole-body metabolism is the 
basis for developing effective treatments of NAFLD. 
 
1.3. Insulin signaling  
1.3.1. The insulin/PI3K/PKB signaling pathway 
Insulin is indispensable for the regulation of systemic metabolism by stimulating cellular glucose 
uptake and anabolic processes. T2D accounts for up to 95% of diagnosed diabetes cases and is 
characterized by impaired intracellular insulin signaling (postreceptor insulin resistance) (42).  
 
Circulating insulin binds to the extracellular α-subunits of the heterotetrameric INSR, which 
induces conformational changes and facilitates autophosphorylation of tyrosine residues on the 
intracellular part of the membrane-spanning β-subunits of the INSR (43). Upon stimulation, 
INSR activates MAPK/ERK and PI3K/PKB signaling pathway (44). While activation of the 
MAPK/ERK pathway by insulin was found to be less critical, IRS1/2-depent activation of PI3K 
signaling is indispensable for regulation of metabolism by insulin (44).  
 
The PI3K/PKB signaling pathway has been studied extensively and reviewed comprehensively 
elsewhere (44-47). An overview of the PI3K/PKB signaling pathway downstream of insulin is 
shown in Figure 7.  
 
 
 
 10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Simplified view of insulin-stimulated PI3K/PKB signaling and its substrates involved in 
cellular metabolism. The PI3K/PKB pathway is activated downstream of the INSR via binding of the 
regulatory subunit of PI3K (p85) to IRS1/2. This leads to recruitment and activation of the catalytic subunit of 
PI3K (p110). PI3K converts PIP2 to PIP3 at the plasma membrane. PKB binds via its PH-domain to PIP3, 
which facilitates activation of PKB by upstream kinases PDK1 and mTORC2. Upon activation, PKB 
phosphorylates GSK3β, FoxO1 and AS160, which regulate glycogen synthesis, gluconeogenesis and glucose 
uptake, respectively. PKB also activates mTORC1 by inhibiting TSC1/2. Activated mTORC1 upregulates 
mitochondrial biogenesis, inhibits autophagy and induces protein synthesis by regulation of PGC1α, ULK1 as 
well as S6K and 4E-BP1, respectively. PDK1 also activates PKCλ/ζ, which regulates glucose uptake. PKB 
and PKCλ/ζ regulate lipogenic genes, such as SREBP1-c and PPARγ. The insulin/PI3K/PKB pathway is 
negatively regulated by PTP1b, PTEN and PP2A that dephosphorylate and thereby inhibit the INSR, IRS1/2, 
PIP3 and PKB, respectively. PKB activity can also be inhibited by binding partners, such as TRB3. Negative 
feed-back loops are implemented to downregulate insulin signaling. GSK3β, mTORC1 and S6K can 
phosphorylate IRS on serine residues, which lead to ubiquitination and proteolytic breakdown. 4E-BP1, 
eIF4E-binding protein 1; AS160, AKT substrate 160; GLUT4, solute carrier family 2; GYS1, glycogen 
synthase; ME1, malic enzyme 1; PDK1, 3-phosphoinositide dependent protein kinase-1; S6, ribosomal protein 
S6; SCD, stearoyl-CoA desaturase; TRIB3, tribbles homolog; ULK1, unc-51-like kinase. Image and figure 
legend were adapted from (43). 
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The activity of PI3K/PKB signaling downstream of insulin is modulated by diverse physiological 
stimuli and insulin-independent mechanisms to adapt cellular insulin response to local nutrient 
and energy level. For instance, mTORC1 is part of the insulin signaling pathway regulating 
anabolic processes, such as cellular growth, mitochondrial biogenesis, protein synthesis and de 
novo lipogenesis (43). Upon insulin stimulation, PKB phosphorylates and inhibits TSC2 leading 
to accumulation of Rheb-GTP, which activates mTORC1 (48). mTORC1 is also activated by 
amino acids (49). In the presence of amino acids Rag GTPases are loaded with GTP (49). 
mTORC1 binds to the Rag GTP complex probably at lysomes facilitating its activation by Rheb-
GTP (48, 49). Conversely, mTORC1 activity is inhibited at low cellular energy levels (49). A 
high AMP to ATP ratio, e.g. due to oxygen or glucose deprivation, activates AMP-activated 
protein kinase (AMPK). AMPK inhibits mTORC1 in two ways; by antagonizing Rheb-
dependent activation of mTORC1 through stimulation of TSC2 and by phosphorylating Raptor 
that enables binding of 14-3-3 (48-50). These regulatory mechanisms indicate that mTORC1 has 
a central role in integrating systemic and cellular metabolism (Figure 8).  
 
  
 
 
 
 
 
 
Figure 8. Insulin and insulin-
independent regulation of 
mTORC1. Insulin activates 
mTORC1 in response to systemic 
nutrient levels. In addition, 
mTORC1 activity is dependent on 
local nutrient and energy status 
such as amino acids and oxygen 
level. Image adapted from (48). 
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mTORC2 is activated by growth factors, but the underlying mechanisms are poorly understood. 
Recently, it was shown that mTORC2 activity is dependent on its association with ribosomes, 
which is stimulated by insulin in a PI3K-dependent manner (51). It was proposed that this 
mechanism links mTORC2 activity to the growth capacity of the cell, which is determined by 
ribosomal content (51). Zanzilla et al showed that this mechanism has a functional role in 
tumorigenesis (51). It would be interesting to investigate the role of mTORC2-ribosome 
interaction in the regulation of systemic metabolism.  
 
Insulin signaling is antagonized by stress kinases upon inflammation and cellular stress. In an 
evolutionary perspective this is beneficial by reserving nutrients for tissue repair or pathogen 
defense (52). However, this is also considered to be the underlying mechanism of obesity-
induced / acquired insulin resistance leading to complications such as cardiovascular disease, 
NAFLD and T2D. 
 
1.3.2. Mechanisms of obesity-induced / acquired insulin resistance 
Inflammation and ectopic lipid accumulation in cells have a central role in the development of 
obesity-induced insulin resistance. They interfere with the action of insulin by different means, 
which can also be in an interconnected, synergistic manner.  
 
Obesity is associated with a low-grade, chronic inflammatory state (53). Despite extensive 
research in this field, the etiology of low-grade inflammation is not yet fully understood. Several 
mechanisms such as lipotoxicity, higher permeability of the intestine for inflammatory 
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substances (e.g. liposaccharides) and an inflammatory nature of nutrients are proposed to trigger 
inflammation in the context of obesity (53, 54). Low-grade inflammation manifests 
predominantly in the adipose tissue, but also affects liver, skeletal muscle, pancreas and brain 
(53). It is characterized by infiltrating proinflammatory M1-like macrophages, mast cells, natural 
killer cells and T-cells leading to increased levels of cytokines such as tumor necrosis factor α 
(TNFα), interleukin-6 (IL-6) and interleukin-1β (IL-1β) in affected tissues (8, 53). This 
inflammatory environment leads to activation of stress kinases such as JNK, IKKβ and PKCθ in 
adipocytes, myocytes and hepatocytes in a paracrine- as well as an endocrine-manner (8). The 
activation of JNK, IKKβ and PKCθ inhibits insulin signaling by phosphorylation and 
destabilization of IRS1 (8, 38, 53, 54). JNK and IKKβ also activate an inflammatory response in 
target cells (Figure 9) (8, 38, 54). 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Insulin resistance due 
to elevated cytokine and free 
fatty acids concentrations. The 
activation of IKK and JNK 
downstream of cytokines and 
free fatty acids leads to insulin 
resistance by inhibition of IRS1/2 
and the expression of 
inflammatory genes. Image 
adapted from (55). 
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Ectopic lipid accumulation in cells also interferes with insulin signaling by activating JNK and 
PKCθ in a direct and an indirect manner. Lipids, such as eicosanoids, phosphoinositides, 
ceramides and DAG are central components of intracellular signaling mechanisms and are 
involved in the regulation of cellular processes including metabolism (54). The intracellular 
levels of ceramids and DAG are known to be elevated in obese patients, in particular in 
myocytes and hepatocytes (38). DAG and ceramide directly interfere with insulin signaling by 
inhibiting IRS1/2 through PKCθ activation and by blocking of PKB via PP2A and PKCζ 
activation, respectively (Figure 10) (8, 54).  
 
 
 
 
 
 
 
 
 
 
Intracellular accumulation of lipids can also lead to cellular stress by impairing the function of 
lipid-metabolizing organelles, such as ER and mitochondria (38, 54). Impaired ER function leads 
to oxidative stress by radical oxygen species (ROS) formation and activation of the unfolded 
protein response (UPR) (38, 54). Both, oxidative stress and UPR activate JNK, which blocks 
insulin signaling (38, 54). Oxidative and ER stress can additionally trigger inflammatory 
 
 
 
Figure 10. Inhibition of 
insulin action by DAG and 
ceramides. Intracellular 
DAG and ceramide 
concentrations are elevated 
by excessive energy intake 
and block insulin signaling 
by activation of nPKCs (e.g. 
PKCθ), PKCζ and PP2A. 
Image adapted from (8). 
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response via JNK and IKKβ activation (53, 54). Circulating free fatty acids also provoke a 
inflammatory response by binding to Toll-like receptors (TLR), such as TLR2 and TLR4 (Figure 
9 and 10) (54). For instance, bone marrow derived dendritic cells and pancreatic islets from 
TLR2-deficient mice had a diminished NEFA-induced inflammatory response (56). While body 
weights are similar to controls, TLR2-deficient mice displayed reduced tissue inflammation and 
an increase in energy expenditure accompanied by improved glucose tolerance and insulin 
sensitivity as well as reduced hepatic lipid content (56).  
 
IL-1β has a major role in obesity-induced inflammation and insulin resistance and promotes the 
progression of insulin resistance to T2D by its toxic effects on β-cells (57, 58). Metabolic stress 
such as high glucose level and oxidative stress is sensed by the inflammasome NLR family, 
pyrin domain containing 3 (NLRP3) which induces secretion of IL-1β (57, 58). Notably, IL-1 
receptor antagonists improve insulin sensitivity as well as function and survival of β-cells and 
have now been successfully used in the treatment of T2D (57-59).  
 
1.4. Modified insulin signaling and its pathophysiology in mice 
1.4.1. Mice with targeted deletion of genes implicated in insulin signaling 
There is a high demand for new therapies to counter the increasing incidence of obesity, T2D 
and related comorbidities such as NAFLD. Mouse models have been used extensively to define 
the physiological role of effectors and regulators of the insulin signaling pathway in metabolism 
and related disorders. Examples of mouse models with targeted deletion of genes implicated in 
insulin signaling are shown in Table 1. 
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Gene Deleted in Insulin sensitivity 
Glucose 
tolerance Further characteristics Refs 
Ptp1b 
whole body + + protected against diet-induced diabetes (60) 
skeletal 
muscle + + 
protected against diet-induced insulin 
resistance (61) 
hepatocytes + + 
reduced hepatic lipid content after 5 
weeks of a high fat diet; protected against 
diet-induced insulin resistance 
(62) 
Insr 
whole body nr nr 
neonatal mice display hyperglycemia and 
hyinsulenimia, develop ketoacidosis and 
die within 7 days after birth 
(63) 
skeletal 
muscle uc uc 
reduced skeletal muscle glucose uptake; 
elevated serum triglycerides and FFAs; 
enhanced adiposity 
(64, 
65) 
hepatocytes - - 
hyperglycemic; hyperinsulemic; 
progressive hepatic dysfunction; 
atherosclerosis when fed with atherogenic 
diet 
(66, 
67) 
adipocytes + + reduced fat mass; prolonged lifespan (68, 69) 
Irs1 whole body - IPGTT: -   OGTT: uc reduced body size 
(70, 
71) 
Irs2 whole body - - β-cell dysfunction (72) 
Pik3r1 
whole body 
(only p85α) 
+ + 
loss of p85α only is compensated by 
p50α, which generates increased level of 
PIP3 
(73) 
whole body 
(p50α, p55α, 
p85α) 
nr + 
perinatal lethality; necrosis in liver and 
brown adipose tissue (74) 
Gsk3α whole body + + 
increased hepatic glycogen content; 
reduced adipose tissue mass (75) 
Gsk3β 
whole body  
(-/-) nr nr embryonic lethal (76) 
whole body 
(+/-) nr nr ameliorates genetically-induced diabetes (76) 
panc β-cells nr + increased pancreatic β-cell mass; 
protected against diet-induced diabetes 
(77) 
hepatocytes uc uc no distinct metabolic phenotype (78) 
skeletal 
muscle + + increased muscle glycogen content (78) 
 
Table 1. Mouse models with targeted deletion of genes implicated in insulin signaling. IPGTT, 
intraperitoneal glucose tolerance test; nr, not reported; OGTT, oral glucose tolerance test; panc, 
pancreatic; uc, unchanged; +, improved; -, reduced; (-/-), homozygous; (+/-), heterozygous. Table 
adapted from (43, 79). 
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Gene Deleted in Insulin sensitivity 
Glucose 
tolerance Further characteristics Refs 
Tsc1 
 
panc β-cells - + 
increased pancreatic β-cell mass; 
improved glycemic control in young mice; 
obesity in old mice 
(80) 
hepatocytes - - 
protected against diet-induced hepatic 
steatosis 
(81, 
82) 
Tsc2 panc β-cells nr + increased pancreatic β-cell mass (83) 
mTOR skeletal muscle uc uc 
increased muscle glycogen content; 
progressive muscle dystrophy; premature 
death 
(84) 
Rictor 
hepatocytes - - hypolipidemia; reduced hepatic lipid and glycogen content (85) 
skeletal 
muscle nr nr no phenotypical changes reported (86) 
Raptor 
skeletal 
muscle nr - 
increased muscle glycogen content; 
progressive muscle dystrophy; premature 
death 
(86) 
adipocytes nr + protected against diet-induced obesity and hypercholesterolemia (87) 
S6k whole body + - 
reduced pancreatic β-cell mass; 
hypoinsulinemia; protected against age- 
and diet-induced obesity and insulin 
resistance 
(88, 
89) 
 
Table 1 (cont.). Mouse models with targeted deletion of genes implicated in insulin signaling. 
IPGTT, intraperitoneal glucose tolerance test; nr, not reported; OGTT, oral glucose tolerance test; panc, 
pancreatic; uc, unchanged; +, improved; -, reduced; (-/-), homozygous; (+/-), heterozygous. Table 
adapted from (43, 79). 
 
These mouse models do not only reveal the role of respective genes in metabolic control, but 
also show that distinct modification of insulin signaling can be advantageous in normal as well 
as pathological conditions. For instance, PTP1b-deficient mice have improved glucose tolerance 
and insulin sensitivity and are protected against diet-induced insulin resistance most likely due to 
enhanced tyrosine phosphorylation of INSR and IRS1 (60). However, effectors of the insulin 
signaling pathway also act downstream of diverse growth factors regulating cell survival, 
proliferation and self-renewal. Thus, deletion of negative regulators of insulin signaling includes 
the risk of adverse effects such as tumorigenesis (43, 90).  
 18 
 
 
The role of insulin response on metabolic control is highly dependent on the targeted tissue(s). 
Neonatal mice with whole-body INSR-deficiency have increased blood glucose and insulin 
concentrations, develop diabetic ketoacidosis and die within 7 days after birth (63). Liver-
specific deletion of Insr in mice results in impaired glucose tolerance and insulin sensitivity and, 
when fed a high fat diet, these mice develop a severe atherosclerosis (66, 67). In contrast, mice 
with adipocyte-specific deletion of the Insr have reduced fat mass, are protected against age-
related obesity and insulin resistance and were found to have a prolonged lifespan (68, 69). Thus, 
dependent on the targeted tissue, inhibition of insulin signaling can have a favorable or 
deteriorative outcome. 
 
The effects of mTORC1-deficiency by deleting Raptor on systemic metabolism were also found 
to be dependent on the targeted tissues. While skeletal muscle-specific deletion of Raptor leads 
to progressive muscle dystrophy and glucose intolerance, mice with adipocyte-specific Raptor-
deficiency were protected against diet-induced obesity and insulin resistance due to increased 
energy expenditure in adipocytes (43, 86, 91). 
 
These findings indicate that activation as well as inhibition of insulin signaling in distinct tissues 
could be more advantageous than a systemic modification in the treatment of insulin resistance 
and related complications. 
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1.4.2. The role of PTEN and PKB in whole-body metabolism and NAFLD development 
PTEN is frequently mutated in many types of cancer such as glioblastoma multiforme, prostate 
and breast cancer (92). PTEN acts as a tumor suppressor by antagonizing PI3K/PKB signaling 
via PIP3 dephosphorylation downstream of diverse growth factors such as epidermal growth 
factor (EGF), hepatocyte growth factor (HGF) and vascular endothelial growth factor (VEGF) 
(93). Recently, it was shown that PTEN has an additional, phosphatase-independent tumor 
suppressive function by inhibiting nuclear anaphase-promoting complex/cyclosome – CDC20 
homologue 1 (APC-CDH1) complex (92, 94). As PTEN negatively regulates PI3K/PKB 
signaling, it also antagonizes insulin signaling. Interestingly, patients having PTEN mutations 
display improved insulin sensitivity as evidenced by 60% lower fasting insulin concentration and 
reduced insulin concentration by 67% in the area under the curve during an oral glucose 
tolerance test (95). 
 
Homozygous deletion of Pten in mice causes embryonic lethality (96, 97). Pten-haplodeficient 
(Pten+/-) mice are viable, but frequently develop tumors in liver, adrenal glands and the thyroid 
(96-98). Increased tumorigenesis was also observed in mice with tissue-specific deletion of Pten 
in pancreas, prostate and mammary glands (99-101). Notably, Pten+/- mice display an improved 
glucose tolerance and insulin sensitivity with enhanced glucose uptake in the skeletal muscle 
(102). Improved glycemic control was also observed in mice lacking PTEN specifically in 
pancreas, adipose tissue and skeletal muscle (Table 2) (103-105).  
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Gene Deleted in Insulin 
sensitivity 
Glucose 
tolerance 
Further characteristics Refs 
Pten 
whole body 
(-/-) nr nr embryonic lethal (102) 
whole body 
(+/-) + + 
protected against genetically-induced 
diabetes; spontaneous tumor development 
(98, 
102, 
106) 
pancreas nr nr 
hypoglycemia; hypoinsulinemia; protected 
against streptozotocin- and diet- induced 
diabetes 
(103) 
skeletal 
muscle 
uc + protected against diet-induced insulin 
resistance and diabetes 
(105) 
adipocytes + + resistant to streptozotocin-induced diabetes (107) 
hepatocytes nr + 
age-dependent hepatic steatosis and its 
progressive forms 
(108, 
109) 
 
Table 2. Overview of mouse models for PTEN. nr, not reported; uc, unchanged; +, improved; -, 
reduced; (-/-), homozygous; (+/-), heterozygous. Table adapted from (43). 
 
Importantly, mice with a hepatocyte-specific deletion of Pten show spontaneous accumulation of 
hepatic lipids starting at 10 weeks of age and develop severe hepatic steatosis and hepatocellular 
carcinoma in an age-dependent manner (108, 109). Overall, the reported phenotype is similar to 
the pathology of human NAFLD and its forms of progression. It was proposed that hepatic lipid 
accumulation is due to hepatocyte-intrinsic processes such as increased de novo lipogenesis 
driven by hyperactivated PKBβ (108, 109). In line with these findings, mice that overexpress 
Pten were shown to be protected against diet-induced hepatic steatosis (110). The authors 
proposed that enhanced energy expenditure in the brown adipose tissue improves metabolic 
control (110). The protection against hepatic steatosis, however, could also be due to diminished 
PKB activation in the liver, which was not addressed in this study. 
 
The PKB serine/threonine protein kinase family consists of three evolutionary conserved 
isoforms (111). PKBα (AKT1), PKBβ (AKT2) and PKBγ (AKT3) are encoded by individual 
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genes and located on different chromosomes (111). The amino acid sequence of PKB isoforms is 
identical by approximately 80% and they form the same protein structure, including a N-terminal 
pleckstrin homology (PH), a catalytic and a C-terminal regulatory domain (43, 112). PKBβ is 
considered to be the major isoform downstream of the insulin receptor. Remarkably, a mutation 
in the kinase domain of PKBβ (arginine to histidine at position 274, R274H) that greatly reduces 
kinase activity of PKBβ was identified in a family with autosomal dominant inherited severe 
insulin resistance (113). PKBβR274H was shown to act in a dominant-negative manner in that its 
overexpression blocks the inhibition of forkhead box protein A2 (FOXA2) in HepG2 cells and 
impairs adipocyte differentiation in vitro (43, 113). Conversely, patients with constitutive 
activation of PKBβ due to a mutation in the PH-domain (E17K) have severe fasting 
hypoglycemia (114).  
 
Mice lacking PKBγ do not show metabolic alterations (115, 116). PKBα-deficient mice 
apparently have improved glycemic control and are protected against diet-induced obesity due to 
enhanced energy expenditure (Table 3) (115, 117). In line with the role of PKBβ in humans, 
Pkbβ-deficient mice develop severe insulin resistance and a diabetes mellitus-like syndrome due 
to hepatic and skeletal muscle insulin resistance (118, 119).  
 
Pkbβ-deficiency was found to protect against genetically- and diet-induced NAFLD. Whole-
body as well as hepatocyte-specific deletion of Pkbβ inhibits the development of hepatic 
steatosis in mice with hepatocyte-specific Pten-deficiency, leptin-deficient mice and mice fed a 
high fat diet (120-122). 
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Gene Deleted in Insulin sensitivity 
Glucose 
tolerance Further characteristics Refs 
Pkbα 
whole body + + 
reduced body size; increased neonatal 
mortality; protected against diet-induced 
obesity and insulin resistance 
(115, 
123) 
skeletal  
muscle nr nr 
not protected against diet-induced 
obesity (117) 
brain nr nr not protected against diet-induced obesity (117) 
Pkbβ 
whole body - - 
diabetes-like phenotype with 
compensatory increase in pancreatic β-
cell mass; protected against genetically- 
and diet-induced hepatic steatosis 
(115, 
118, 
120, 
122, 
124) 
hepatocytes nr nr protected against genetically- and diet-induced hepatic steatosis (122) 
Pkbα/ 
Pkbβ 
hepatocytes nr - constitutive active FoxO1 impairs adaption to fasted and fed conditions  (125) 
Pkbγ whole body uc uc impaired postnatal brain development; no obvious metabolic phenotype 
(115, 
116) 
 
Table 3. Overview of mouse models for PKB isoforms. nr, not reported; uc, unchanged; +, 
improved; -, reduced. Table adapted from (43). 
 
Loss of PKBβ leads to downregulation of lipogenic genes such as SREBP-1c, FAS and ACC and 
reduced de novo lipogenesis in the liver (120, 122). But the regulation of lipogenic genes by 
PKBβ is also context-dependent. While in mice with hepatocyte-specific Pten-deficiency and 
leptin-deficiency the expression of lipogenic genes was found to be dependent on PKBβ, the 
expression was not altered in Pkbβ-deficient mice fed with normal chow or a high-fat diet 
enriched in simple carbohydrates (Surwit diet) (109, 120, 122).  
  
The accumulation of lipids in the liver does not only depend on hepatic PTEN and PKBβ but, as 
shown in the following sections, also on PTEN and PKBβ activity in skeletal muscle via 
systemic interactions. 
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2. Scope of the thesis 
Previously, it was shown that accumulation of lipids in the liver of mice with hepatocyte-specific 
deletion of Pten depends on hepatic PKBβ. But the role of PTEN and PKBβ in peripheral insulin 
sensitive tissues on accumulation of hepatic lipids was not addressed. The aim of this thesis is to 
characterize the effects of systemically perturbed PTEN/PKBβ signaling on accumulation of 
lipids in the liver.  
 
To this end we used mice with whole-body Pten-haplodeficiency (Pten+/-/Pkbβ+/+) that have 
reduced PTEN level in all tissues such as liver, pancreas, adipose tissue and skeletal muscle. 
Pten-haplodeficient mice lacking PKBβ (Pten+/-/Pkbβ-/-) were used to dissect the role of PKBβ 
in this mouse model. The liver, pancreas, adipose tissue and skeletal muscle were characterized 
by histology and/or the analysis of insulin signaling by Western blotting and quantitative real-
time PCR (qRT-PCR). To assess the effects of PKBβ activity in skeletal muscle on hepatic lipid 
content, PKBβ mutants were expressed in skeletal muscle of Pten+/+/Pkbβ+/+ and Pten+/-/Pkbβ+/+ 
mice using adeno-associated virus 8 as a vector. 
 
The present study shows that hepatic lipid content is reduced by 2-fold in Pten+/-/Pkbβ+/+ 
compared to control mice despite increased activation of PKBβ and upregulation of lipogenic 
genes in the liver. We found that an enhanced skeletal muscle insulin response mediated by 
PKBβ reduces the accumulation of hepatic lipids in both Pten+/+/Pkbβ+/+ and Pten+/-/Pkbβ+/+ 
mice. Our results support the notion that skeletal muscle insulin resistance is a central factor in 
the development of NAFLD. Thus, improving the insulin response in skeletal muscle by physical 
exercise and/or insulin sensitizer may be an effective option for treatment of NALFD.  
 24 
 
3. Results 
3.1. General notes 
The results obtained during my thesis are shown in the following manuscript entitled 
“AKT2/PKBβ activation in skeletal muscle regulates hepatic lipid content in Pten-haplodeficient 
mice”. 
 
Parts of the text in the manuscript were taken from the summary, introduction, scope of the thesis 
and general discussion of this thesis.  
 
The numbering of references and figures of the manuscript is separate to that from the 
introduction and general discussion meaning that the first reference and the first figure of the 
manuscript is numbered as “1”.  
 
3.2. List of contributions to the manuscript 
Oliver Tschopp and Markus Niessen were involved in all steps of this project including study 
design, acquisition of data, analysis and interpretation of data and manuscript writing. 
 
Andreas Geier, Giagten A. Spinas and Brian A. Hemmings supervised the project and 
critically revised the manuscript. 
 
Debby Hynx assisted in vivo work by supporting colony maintenance, measurement of blood 
glucose level and tissue sampling. 
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Heidi Seiler and Sandrine Bichet assisted the staining of histological sections. 
 
Laurent Gelman, Aaron Ponti, Steve Bourke, Arno Doelemeyer and Patrick Schwarb 
supported image acquisition, quantitative analysis of histological specimen and gave technical 
advice. 
 
Josephine Juettner taught me how to produce adeno-associated virus 8 and gave technical 
advice.  
 
Patrick King edited the manuscript. 
 
I was substantially involved in all steps of this project including study design, acquisition of data, 
analysis and interpretation of data, figure preparation and manuscript writing.  
 
 
3.3. AKT2/PKBβ activation in skeletal muscle regulates hepatic lipid content 
in Pten-haplodeficient mice 
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Abstract 
Background & Aims: Non-alcoholic fatty liver disease (NAFLD) is a major health problem and 
occurs frequently in the context of metabolic syndrome and type 2 diabetes mellitus. Hepatocyte-
specific Pten-deficiency in mice was shown previously to result in hepatic steatosis due to 
hyperactivated AKT2. However, the role of peripheral insulin-sensitive tissues on PTEN- and 
AKT2-dependent development of NAFLD has not been addressed. 
Methods: Effects of systemically disturbed PTEN/AKT2 signaling on hepatic lipid content were 
studied in Pten-haplodeficient (Pten
+/-
/Akt2
+/+
) mice and Pten-haplodeficient mice lacking Akt2 
(Pten
+/-
/Akt2
-/-
). The liver and skeletal muscle were characterized by histology and/or the 
analysis of insulin signaling. To assess the effects of AKT2 activity in skeletal muscle on hepatic 
lipid content, AKT2 mutants were expressed in skeletal muscle of Pten
+/+
/Akt2
+/+
 and Pten
+/-
/Akt2
+/+ 
mice using adeno-associated virus 8 as vector. 
Results: Pten
+/-
/Akt2
+/+
 mice were found to have a more than 2-fold reduction in hepatic lipid 
content, at a level similar to that observed in Pten
+/-
/Akt2
-/- 
mice. Insulin signaling in the livers of 
Pten
+/-
/Akt2
+/+ 
mice was enhanced, indicating that extra-hepatic factors prevent lipid 
accumulation. The skeletal muscle of Pten
+/-
/Akt2
+/+ 
mice also showed enhanced insulin 
signaling. Skeletal muscle-specific expression of constitutively active AKT2 reduced hepatic 
lipid content in Pten
+/+
/Akt2
+/+ 
mice, and dominant negative AKT2 led to an increase in 
accumulation of hepatic lipids in both Pten
+/+
/Akt2
+/+ 
and Pten
+/-
/Akt2
+/+ 
mice.  
Conclusion: The results of this study demonstrate that AKT2 activity in skeletal muscle 
critically affects lipid accumulation in the livers of Pten
+/+
/Akt2
+/+ 
and Pten
+/-
/Akt2
+/+ 
mice, and 
emphasize the role of skeletal muscle in the pathophysiology of NAFLD. 
Keywords: NAFLD; liver; metabolism  
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Introduction 
Non-alcoholic fatty liver disease (NAFLD) is a major complication in patients with metabolic 
syndrome and type 2 diabetes mellitus (T2D) and affects approximately one-third of adults and 
about 10% of children in developed countries [1-3]. NAFLD is characterized by the 
accumulation of predominantly macrovesicular lipid droplets in the cytoplasm of hepatocytes 
[4]. A substantial number of patients with NAFLD develop necro-inflammatory changes in the 
liver (non-alcoholic steatohepatitis, NASH), which may lead to cirrhosis and eventually to 
hepatocellular carcinoma (HCC) and hepatic failure [4,5]. Diverse factors, such as oxidative and 
endoplasmatic reticulum stress and hepatocyte death have been proposed to trigger progression 
of NAFLD to NASH, but the individual impacts of these factors remain controversial [6-10]. 
Although the association of NAFLD with insulin resistance and T2D is well known, the 
molecular mechanisms have not been fully elucidated. It is considered that insulin resistance of 
skeletal muscle and/or selectively impaired hepatic insulin signaling drive ectopic lipid 
accumulation in the liver [11-13]. 
 
Insulin is indispensable for the regulation of systemic metabolism. It stimulates cellular glucose 
uptake and induces anabolic processes, largely mediated by AKT [14]. PTEN negatively 
regulates insulin signaling by antagonizing activation of AKT [14]. PTEN and AKT also act 
downstream of several other stimuli and are pivotal regulators of elementary cellular processes 
such as proliferation, differentiation, survival and cell growth [15]. Consequently, deregulation 
of PTEN and/or AKT often results in disease, such as cancer and neurodegeneration [16,17]. 
Stimuli- and context-specificity of AKT are, at least partially, mediated by the recruitment of 
different isoforms of AKT (AKT1/PKB, AKT2/PKB, AKT3/PKB) [18,19]. AKT2 is 
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considered to be the major isoform downstream of the insulin receptor and mice lacking Akt2 
develop severe insulin resistance and a T2D-like syndrome due to hepatic and skeletal muscle 
insulin resistance [20,21].  
 
PTEN-deficiency results in the hyperactivation of AKT. Whilst homozygous deletion of Pten in 
mice causes embryonic lethality, Pten-haplodeficient (Pten
+/-
) mice are viable [22]. Such mice 
show improved glucose tolerance and insulin sensitivity, but aged Pten
+/-
 mice frequently 
develop tumors in liver, colon and thyroid glands [22,23]. Importantly, mice with a hepatocyte-
specific deletion of Pten show spontaneous accumulation of hepatic lipids starting at 10 weeks of 
age and severe hepatic steatosis and HCC develop in an age-dependent manner [24,25]. Overall, 
the reported phenotype is similar to the pathology of human NAFLD and its forms of 
progression. It was shown that hepatic lipid accumulation in these mice is driven by 
hyperactivated AKT2 in a hepatocyte-autonomous manner [24-26].  
 
However, the metabolic state of the liver also depends on systemic metabolism, which is 
regulated by multiple insulin-sensitive tissues. The physiological role of peripheral insulin-
sensitive tissues in PTEN/AKT2-dependent development of NAFLD has not been addressed. In 
the present study, mice with whole-body Pten-haplodeficiency (Pten
+/-
/Akt2
+/+
) were used to 
analyze the impact of metabolically relevant tissues on hepatic lipid content. Pten-haplodeficient 
mice lacking Akt2 (Pten
+/-
/Akt2
-/-
) were used to dissect the role of AKT2 in this mouse model.  
 
In contrast to hepatic steatosis reported in mice with a hepatocyte-specific deletion of Pten, we 
show here that the hepatic lipid content of Pten
+/-
/Akt2
+/+
 mice is more than 2-fold lower than 
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that of Pten
+/+
/Akt2
+/+
 control mice and at a level similar to that observed in Pten
+/-
/Akt2
-/- 
mice. 
In contrast to the reduced lipid content, Pten
+/-
/Akt2
+/+
 mice showed enhanced insulin signaling 
in the liver, in line with the notion that extra-hepatic factors prevent lipid accumulation in the 
livers of these mice. Analyses of peripheral insulin-sensitive tissues indicated that enhanced 
AKT2 activation in skeletal muscle reduces hepatic lipid accumulation in Pten
+/-
/Akt2
+/+ 
mice. 
Significantly, skeletal muscle-specific expression of constitutively active AKT2 reduced hepatic 
lipid accumulation in Pten
+/+
/Akt2
+/+ 
mice and dominant negative AKT2 led to increases in 
hepatic lipid content in both Pten
+/+
/Akt2
+/+ 
and Pten
+/-
/Akt2
+/+ 
mice.   
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Material & Methods 
Mice 
All animal experiments were performed in accordance with Swiss Federal Animal Regulations 
and approved by the Veterinary Office of Zurich and Basel, Switzerland. Mice with whole-body 
targeted deletion of Pten and Akt2 were described previously and were in a C57BL/6 background 
after at least 6 backcrosses [21,27]. Pten
+/+
/Akt2
+/+
, Pten
+/-
/Akt2
+/+ 
and Pten
+/-
/Akt2
-/- 
mice were 
obtained by crossing Pten
+/-
/Akt2
+/- 
mice. The experimental mice were 20- to 22-week-old males. 
Mice were fasted by removing food for 8 h during the dark cycle. Fasted-refed mice were refed 
for 2 h after 8 h of fasting. Insulin stimulation was performed in fasted and terminally 
anesthetized mice by injection of human recombinant insulin at 1 U / kg of body weight (Novo 
Nordisk, Kuesnacht, Switzerland) via the inferior vena cava; samples were collected after 20 
min. Mice were housed in groups with a 12-h dark-light cycle and free access to food and water, 
unless otherwise indicated.  
 
Vector production and administration 
Adeno-associated virus (AAV) 8 vectors were generated by triple plasmid transfection of 
HEK293T cells using jetPEI (Polyplus, Illkirch, France). AAV transplasmid (serotype 8) and 
helper plasmid were obtained from Penn Vector Core, Philadelphia, PA. myr-AKT2 and 
AKT2
K180A 
were cloned as described previously and cloned into AAV expression vector 
containing a CMV promoter and a 2A-GFP reporter gene [28,29]. Viral particles were purified 
using a discontinuous iodixanol gradient as previously described [30]. Titers were determined by 
quantitative real-time polymerase chain reaction (qRT-PCR). 2 x 10
11 
genome copies of AAV8 
viral particles were administered to 4-day-old mice by intraperitoneal injection. Skeletal muscle-
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specific transgene expression results from selective retention of the vector DNA [31]. Mice used 
for subsequent metabolic analyses were 18- to 20-week-old.  
 
Analysis of metabolic parameters in blood and tissues 
Glucose levels were measured in tail vein blood using a glucose meter Freestyle (Disetronic, 
Burgdorf, Switzerland). Glucose tolerance tests were performed with fasted mice by 
intraperitoneal injection of 2 g D-(+)-glucose anhydrous / kg of body weight (Fluka, Buchs, 
Switzerland) and glucose levels measured at indicated time points. Triglyceride contents of 
skeletal muscle and liver and glycogen contents of skeletal muscle were determined as described 
previously [32].  
 
Histology and quantitative analysis 
Hematoxylin and eosin (H&E) and Oil Red O (Sigma-Aldrich, Saint Louis, MO) staining were 
performed according to standard protocols on paraffin and frozen sections, respectively. For 
fluorescent staining of lipids, frozen sections were fixed in 10% formaldehyde, incubated with 1 
µg/ml BODIPY493/503 (Invitrogen, Carlsbad, CA) in 150 mM NaCl for 20 min at room 
temperature, and counterstained with 4′,6-Diamidino-2-phenylindole dihydrochloride (DAPI) 
(Sigma-Aldrich, Saint Louis, MO). BOPIPY493/503-stained areas relative to total tissue areas 
were quantified using Imaris software (Bitplane, Zurich, Switzerland). GFP staining was 
performed using Ventana DiscoveryXT (Roche Diagnostics, Mannheim, Germany) with a 
customized procedure for fluorescent staining. Slides were pre-treated with mild CC1, incubated 
with anti-GFP antibody (Invitrogen, Carlsbad, CA) for 1 h at 37°C,  incubated with goat anti-
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rabbit conjugated with Alexa fluor 647 (Invitrogen, Carlsbad, CA) for 32 min at 37°C and 
counterstained manually with DAPI. 
 
Western blot analysis 
Western blot analysis was performed using standard protocols (GE Healthcare, 
Buckinghamshire, UK). Images were captured on film or by BioSpectrum Imaging System 
(UVP, Cambridge, UK). Signal intensities were quantified by photodensitometry after 
background subtraction relative to -Actin and normalized to fasted Pten+/+/Akt2+/+ mice. 
Antibodies against the following proteins were used: PTEN (Nicholas K. Tonks, Cold Spring 
Harbor Laboratory, USA), PTEN, pan-AKT, AKT1, AKT2, p-AKT S473, p-AKT T308, 
GSK3/, p-GSK3, FoxO1, p-FoxO1 (Cell Signaling, Beverly, MA) and β-Actin (Santa Cruz 
Biotechnology, Santa Cruz, CA).  
 
Quantitative real time PCR 
Total RNA was isolated from tissues using TRIZOL (Invitrogen, Carlsbad, CA) following the 
manufacturer's instructions. cDNA synthesis was performed with M-MuLV reverse transcriptase 
(New England BioLabs, Ipswich, MA) according to the manufacturer’s instructions. qRT-PCR 
reactions were performed using SYBR Green (Invitrogen, Carlsbad, CA) on ABI Prism 7000 or 
StepOnePlus Real-Time PCR System (Applied Biosystems, Rotkreuz, Switzerland). Primer 
sequences were obtained from PrimerBank [33]. The primers used and the corresponding 
PrimerBank ID were Acc (ID: 14211284a1), Fas (ID: 30911099a2), G6Pase (ID: 31982353a1), 
Gck (ID: 31982798a1), Pepck (ID: 7110683a1), Pgc1a (ID: 238018130b1), Ppara (ID: 
31543500a1), Pparg (ID: 6755138a2) and Srebp-1c (ID: 14161491a1).  
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Statistical analysis 
All data are presented as means ± standard deviation (SD). Data were subjected to Student's t-test 
for statistical significance (*P <0.05; **P <0.01). The numbers of independent biological 
samples per group used for each analysis are indicated accordingly. 
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Results 
Improved glucose homeostasis in Pten+/-/Akt2+/+ mice depends on AKT2 
Male Pten
+/+
/Akt2
+/+
, Pten
+/-
/Akt2
+/+
 and Pten
+/-
/Akt2
-/- 
mice 20- to 22-week-old were used to 
analyze the effects of systemically perturbed PTEN and AKT2 signaling on hepatic lipid content. 
Western blot analysis of PTEN, AKT2 and AKT1 protein levels in liver, skeletal muscle and 
adipose tissue was performed to validate our mouse model (Fig. 1A, B, Fig. S1).  
 
Pten
+/- 
mice were reported previously to be slightly hypoglycemic with improved glucose 
tolerance, whereas Akt2
-/- 
mice were hyperglycemic and glucose intolerant [20,23,34,35]. Body 
weights and fasting blood glucose concentrations of Pten
+/-
/Akt2
+/+ 
and Pten
+/-
/Akt2
-/- 
mice were 
similar to controls (data not shown, Fig. 1C). However, when randomly fed or refed after fasting, 
Pten
+/-
/Akt2
+/+ 
mice showed a reduction and Pten
+/-
/Akt2
-/- 
mice an increase in blood glucose 
concentrations (Fig. 1 D, E). We performed glucose tolerance tests by intraperitoneal injection of 
glucose to further assess glycemic control. The glucose tolerance of Pten
+/-
/Akt2
+/+ 
mice had 
improved significantly compared to Pten
+/+
/Akt2
+/+ 
control mice (area under the curve -22.2% ± 
18.8%; P <0.05) (Fig. 1F). Interestingly, glucose tolerance of Pten
+/-
/Akt2
-/- 
mice was similar to 
control mice, indicating compensation of acute glucose challenges (Fig. 1F).  
 
These data verify the efficacy of gene targeting in Pten
+/-
/Akt2
+/+ 
and Pten
+/-
/Akt2
-/-
 mice and 
also show that the reduced blood glucose concentration and improved glucose tolerance of 
Pten
+/-
/Akt2
+/+
 mice are dependent on AKT2 activity. 
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Figure 1. Improved glycemic 
control in Pten
+/-
/Akt2
+/+
 mice is 
dependent on AKT2. (A, B) 
Protein levels of PTEN, AKT2, 
AKT1 and pan-AKT in liver (A) 
and skeletal muscle (B) analyzed 
by Western blot. Densitometric 
quantification is shown. n = 
4/group. (C, D, E) Blood glucose 
concentrations from fasted (C), 
random fed (D) and fasted-refed 
(E) mice. n = 5-9/group. (F) Blood 
glucose concentrations in fasted 
mice after intraperitoneal 
administration of glucose were 
measured at the indicated time 
points; respective AUCs are 
shown. n = 7-8/group. AUC, area 
under the curve; data are 
expressed as means ± SD; * P 
<0.05; ** P <0.01.  
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Hepatic lipid content is reduced in both Pten+/-/Akt2+/+ and Pten+/-/Akt2-/- mice  
Mice with a hepatocyte-specific Pten-deficiency spontaneously develop hepatic steatosis [24,25]. 
Here we analyzed the livers of Pten
+/-
/Akt2
+/+
 and Pten
+/-
/Akt2
-/- 
mice to examine the effects of 
systemically perturbed PTEN/AKT2 signaling on hepatic lipid content. 
 
In contrast to the hepatomegaly reported in mice with hepatocyte-specific Pten-deficiency, 
Pten
+/-
/Akt2
+/+
 and Pten
+/-
/Akt2
-/- 
mice displayed only minor changes in liver weights (Fig. 2A) 
[24,25]. Histological analysis of liver sections was performed to examine the accumulation of 
hepatic lipids. Hepatic steatosis was not observed in Pten
+/-
/Akt2
+/+ 
and Pten
+/-
/Akt2
-/- 
mice (Fig. 
2B). 
 
 In particular, lower amounts of lipids were found in liver sections of Pten
+/-
/Akt2
+/+ 
and Pten
+/-
/Akt2
-/- 
mice stained with Oil Red O and BODIPY493/503 compared to Pten
+/+
/Akt2
+/+ 
control 
mice (Fig. 2C, D). The quantification of BODIPY493/503-stained area and measurements of 
hepatic triglycerides confirmed that hepatic lipid content in Pten
+/-
/Akt2
+/+ 
and Pten
+/-
/Akt2
-/- 
mice is reduced by more than 2.3-fold (Fig. 2E, F).  
 
Thus, in contrast to mice with a hepatocyte-specific deletion of Pten, the hepatic lipid content in 
Pten
+/-
/Akt2
+/+ 
mice was reduced to levels similar to those observed in Pten
+/-
/Akt2
-/- 
mice. 
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Figure 2. Reduced hepatic lipid content in Pten
+/-
/Akt2
+/+
 and Pten
+/-
/Akt2
-/-
 mice. (A) 
Liver to body weight ratios. (B, C, D) Representative images of liver sections from fasted 
mice stained with H&E (B), stained for lipids with Oil Red O (C), and stained for lipids and 
DNA with BODPIY493/503 (green) and DAPI (blue), respectively (D). Image inlays show 
part of the depicted area at higher magnification. (E) Relative BODIPY493/503-stained area. 
(F) Hepatic triglyceride content in fasted mice. TG, triglycerides; scale bar = 200 µm; n = 7-
8/group; data are expressed as means ± SD; * P <0.05. 
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Enhanced insulin signaling in the liver of Pten+/-/Akt2+/+ mice is partially dependent on 
AKT2 
Insulin increases hepatic lipid content via inhibition of gluconeogenesis and stimulation of de 
novo lipogenesis [36-38]. Therefore, we examined whether diminished AKT signaling 
downstream of insulin might explain the reduced hepatic lipid content in Pten
+/-
/Akt2
+/+ 
mice and 
if this is dependent on AKT2. 
 
Western blot analysis showed a more than 4.5-fold increase in phosphorylation of AKT at S473 
(p-AKT S473) and T308 in the livers of fasted Pten
+/-
/Akt2
+/+ 
mice (Fig. 3A). In Pten
+/-
/Akt2
-/- 
mice, p-AKT S473 was unchanged but p-AKT T308 was elevated 3-fold (Fig. 3A). Insulin-
stimulated mice were analyzed to further assess activation of AKT. p-AKT S473 but not p-AKT 
T308 was 32% higher in Pten
+/-
/Akt2
+/+ 
mice than in control mice after insulin stimulation (Fig. 
3A). As expected, the insulin-stimulated increase in p-AKT S473 and T308 in Pten
+/-
/Akt2
-/- 
mice was reduced by 72% and 41% compared to control mice, respectively (Fig. 3A). Analysis 
of the phosphorylation of the AKT targets GSK3 and FoxO1 showed an increase in p-GSK3 
during fasting and in p-GSK3 and p-FoxO1 upon insulin stimulation in Pten+/-/Akt2+/+ mice, in 
line with enhanced phosphorylation of AKT (Fig. 3B). Pten
+/-
/Akt2
-/- 
mice displayed increased p-
GSK3 during fasting and increased p-FoxO1 upon insulin stimulation, showing that 
phosphorylation of GSK3 or FoxO1 in these mice is only partially dependent on AKT2 (Fig. 
3B). 
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To further characterize hepatic insulin signaling, the expression levels of gluconeogenic and 
lipogenic genes were analyzed in fasted mice. Whilst FoxO1 phosphorylation did not change 
during fasting, expression of Pepck and G6Pase declined by more than 40% in Pten
+/-
/Akt2
+/+ 
mice (Fig. 3C). AKT2 was previously shown to upregulate expression of lipogenic genes in mice 
with hepatocyte-specific Pten-deficiency and leptin-deficient mice, but not in mice fed with 
normal chow or a specific high-fat diet [26,37].  
 
Notably, the lipogenic genes Srebp1-c and its targets Fas and Acc were upregulated in Pten
+/-
/Akt2
+/+ 
mice (Fig. 3D). In Pten
+/-
/Akt2
-/- 
mice, expression of Srebp1-c, Fas and Acc was high but 
Pparg was downregulated compared to control mice (Fig. 3D). In order to clarify whether -
oxidation contributed to the reduced levels of hepatic lipids in Pten
+/-
/Akt2
+/+ 
and Pten
+/-
/Akt2
-/- 
mice, the expression levels of Ppara and Pgc1a were determined. There was no difference in the 
expression of Ppara or Pgc1a in fasted Pten
+/-
/Akt2
+/+ 
and Pten
+/-
/Akt2
-/- 
compared to control 
mice (Fig. 3E). 
 
Taken together, these data show that hepatic insulin signaling is elevated in Pten
+/-
/Akt2
+/+ 
mice 
and that this is mediated partially by AKT2. Moreover, the data suggest that extra-hepatic 
processes prevent the accumulation of lipids in Pten
+/-
/Akt2
+/+
 liver.  
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Figure 3. Enhanced AKT activation and upregulation of lipogenic genes in the 
liver of Pten
+/-
/Akt2
+/+
 mice are partially dependent on AKT2. (A) Phosphorylation 
of AKT at S473 and T308 and pan-AKT protein levels in the liver of fasted and insulin 
stimulated mice. Densitometric quantification is shown. n = 3-4/group. (B) 
Phosphorylation and protein levels of GSK3 and FoxO1 in the liver of fasted and 
insulin stimulated mice. Densitometric quantification is shown. n = 3-4/group. (C, D, 
E) Relative mRNA levels of gluconeogenic genes (C), lipogenic genes (D) and genes 
involved in -oxidation (E) in the liver of fasted mice. n = 6/group. Data are expressed 
as means ± SD; * P <0.05; ** P <0.01. 
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Increase in glycogen and enhanced AKT signaling in skeletal muscle of Pten+/-/Akt2+/+ 
mice depends on AKT2 
Firstly, we characterized morphology of the pancreas and activation of AKT in the adipose tissue 
of Pten
+/-
/Akt2
+/+ 
mice, but no major changes were observed (Fig. S2, Fig. S3). 
 
It was reported previously that the insulin sensitivity of skeletal muscle influences the 
accumulation of lipids in the liver through redistribution of ingested nutrients [12,39]. 
Furthermore, increased glucose uptake in skeletal muscle was found in Pten
+/-
 mice after insulin 
stimulation [23]. Therefore, we examined whether an insulin response of skeletal muscle is 
involved in the reduction of hepatic lipids in Pten
+/-
/Akt2
+/+ 
mice. 
 
The skeletal muscle of fasted Pten
+/-
/Akt2
+/+ 
mice displayed increased triglyceride content, but 
no difference in glycogen content (Fig. 4A, B). However, glycogen content was increased in 
skeletal muscle of Pten
+/-
/Akt2
+/+ 
mice upon insulin stimulation, but was comparable to controls 
in Pten
+/-
/Akt2
-/- 
mice (Fig. 4C). These results indicate that skeletal muscle of Pten
+/-
/Akt2
+/+ 
mice displays an enhanced insulin response mediated by AKT2.  
 
 
 
 
 
 
 
 
Figure 4. Triglyceride and glycogen contents are increased in skeletal muscle of Pten
+/-
/Akt2
+/+
 but not Pten
+/-
/Akt2
-/-
 mice. (A) Triglyceride content in skeletal muscle of fasted mice. 
n = 6-8/group. (B, C) Glycogen content in skeletal muscle of fasted (B) and insulin-stimulated 
(C) mice. fasted n = 6-8/group; insulin-stimulated n = 3/group. TG, triglycerides; data are 
expressed as means ± SD; * P <0.05. 
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Next we analyzed basal and insulin-dependent activation of AKT and downstream targets in 
skeletal muscle by Western blotting. While AKT phosphorylation in fasted Pten
+/-
/Akt2
+/+ 
mice 
was similar to control mice, fasted Pten
+/-
/Akt2
-/- 
mice displayed a reduction in p-AKT 473 by 
more than 70% (Fig. 5A). There were only minor differences in the phosphorylation of GSK3 
and FoxO1 in fasted Pten
+/-
/Akt2
+/+ 
and Pten
+/-
/Akt2
-/- 
mice (Fig. 5B). Notably, in insulin-
stimulated Pten
+/-
/Akt2
+/+ 
mice, p-AKT S473 but not p-AKT T308 was increased by 28% and p-
GSK3 and p-FoxO1 were increased by more than 40% compared to control mice (Fig. 5A, B).  
In Pten
+/-
/Akt2
-/- 
mice, insulin-induced increase in p-AKT S473 and p-AKT T308 was abrogated 
(Fig. 5A). However, p-GSK3 and p-FoxO1 were induced by insulin in Pten+/-/Akt2-/- mice 
similar to control mice, suggesting phosphorylation of GSK3 and FoxO1 is partially dependent 
on AKT2 in these mice (Fig. 5B). 
 
While the expression of lipogenic genes in skeletal muscle of fasted Pten
+/-
/Akt2
+/+ 
mice was at 
levels similar to controls, there was a trend towards reduced expression of Ppara, as well as a 
significant reduction of Pgc1a mRNA levels by more than 20%, suggesting diminished -
oxidation (Fig. 5C, D). 
 
Taken together, our data reveal an enhanced insulin response of Pten
+/-
/Akt2
+/+ 
skeletal muscle 
that is mediated by AKT2. Hence, AKT2 in skeletal muscle may contribute to the reduction in 
hepatic lipids in Pten
+/-
/Akt2
+/+ 
mice and affect hepatic lipid accumulation in general. 
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Figure 5. AKT signaling is enhanced in skeletal muscle of Pten
+/-
/Akt2
+/+
 mice. (A) 
Phosphorylation of AKT at S473 and T308 and pan-AKT protein levels in skeletal muscle of 
fasted and insulin stimulated mice. Densitometric quantification is shown. n = 3-4/group. (B) 
Phosphorylation and protein levels of GSK3 and FoxO1 in skeletal muscle of fasted and 
insulin stimulated mice. Densitometric quantification is shown. n = 3-4/group. (C, D) Relative 
mRNA levels of lipogenic genes (C) and genes involved in -oxidation (D) in skeletal muscle 
of fasted mice. n = 5-8/group. Data are expressed as means ± SD; * P <0.05; ** P <0.01. 
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Skeletal muscle-specific expression of AKT2 mutants affects hepatic lipid content 
To analyze the effects of AKT2 in skeletal muscle on the accumulation of hepatic lipids and its 
possible contribution to reduced hepatic lipids in Pten
+/-
/Akt2
+/+ 
mice, constitutive active AKT2 
(myr-AKT2) and dominant negative AKT2 (AKT2
K180A
) were expressed specifically in skeletal 
muscle. Adeno-associated virus (AAV) 8 vectors expressing myr-AKT2 and AKT2
K180A 
with a 
GFP reporter gene were produced and skeletal muscle-specific expression was achieved by 
intraperitoneal injection of neonatal Pten
+/+
/Akt2
+/+
 and Pten
+/-
/Akt2
+/+ 
mice [31]. Mice 
expressing the different transgenes in skeletal muscle were designated as Pten
+/+
/2A.GFP, 
Pten
+/+
/myr-AKT2.2A.GFP, Pten
+/+
/AKT2
K180A
.2A.GFP, Pten
+/-
/2A.GFP and Pten
+/-
/AKT2
K180A
.2A.GFP. The efficiency and specificity of transgene expression was validated by 
GFP staining of skeletal muscle and liver (Fig. 6A).  
 
Mice expressing AKT2 mutants in skeletal muscle had body weights and fasted blood glucose 
concentrations similar to GFP-expressing control mice (data not shown). Glucose tolerance tests 
were performed to further assess glycemic control. Pten
+/+
/myr-AKT2.2A.GFP and Pten
+/-
/AKT2
K180A
.2A.GFP showed glucose tolerance similar to the respective control mice. However, 
glucose tolerance of Pten
+/+
/AKT2
K180A
.2A.GFP mice was impaired as evidenced by an increase 
in the area under the glucose curve by 30% (Fig. 6B).  
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Figure 6. Skeletal muscle-specific expression of 2A.GFP, myr-AKT2.2A.GFP and 
AKT2
K180A
.2A.GFP in Pten
+/+
/Akt2
+/+
 and Pten
+/-
/Akt2
 +/+ 
mice. (A) Representative images of 
sections from indicated regions of skeletal muscle and liver stained for GFP (green) and DNA (blue). 
Arrows indicate GFP-positive hepatocytes. Scale bar = 100 µm. (B) Blood glucose concentrations in 
fasted mice after intraperitoneal administration of glucose were measured at the indicated time points. 
Time course of changes in blood glucose concentration are separated according to genotype for a 
better overview. Respective AUCs are shown. n = 7-12/group; AUC, area under the curve; data are 
expressed as means ± SD; * P <0.05, ** P <0.01. 
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Expression of AKT2 mutants in skeletal muscle did not alter liver weights (Fig. 7A). H&E-
staining of liver sections revealed increased lipid accumulation in Pten
+/+
/AKT2
K180A
.2A.GFP 
mice (Fig. 7B). Notably, staining of liver sections with Oil Red O and BODIPY493/503 revealed 
less hepatic lipids in Pten
+/+
/myr-AKT2.2A.GFP mice and an increase in 
Pten
+/+
/AKT2
K180A
.2A.GFP mice relative to Pten
+/+
/2A.GFP controls (Fig. 7C, D). Moreover, 
Pten
+/-
/AKT2
K180A
.2A.GFP mice had a higher lipid content than Pten
+/-
/2A.GFP mice (Fig. 7C, 
D). Importantly, these observations were confirmed by the quantification of BODIPY493/593-
positive stained areas and triglyceride assays (Fig. 7E, F). 
 
 
Taken together, the present data clearly show that enhanced activity of AKT2 in skeletal muscle 
is a key factor in the reduction of hepatic lipid content in Pten
+/-
/Akt2
+/+ 
mice. The significance 
of AKT2 activity in skeletal muscle on accumulation of hepatic lipids is further underlined by 
the effects observed in Pten
+/+
/Akt2
+/+ 
mice expressing AKT2 mutants in the skeletal muscle. 
The higher hepatic lipid content in Pten
+/+
/AKT2
K180A
.2A.GFP compared to Pten
+/-
/AKT2
K180A
.2A.GFP mice, however, indicates the existence of further mechanism(s) influencing 
the accumulation of hepatic lipids in Pten
+/-
/Akt2
+/+ 
mice. 
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Figure 7. Skeletal muscle-specific expression of myr-AKT2 and AKT2
K180A
 affects 
hepatic lipid content. (A) Liver to body weight ratios. (B, C, D) Representative images of 
liver sections stained with H&E (B), for lipids with Oil Red O (C) and for lipids and DNA 
with BODPIY493/503 (green) and DAPI (blue), respectively (D). Image inlays show part of 
the depicted area at higher magnification. (E) Relative BODIPY493/503-stained areas. (F) 
Hepatic triglyceride content in fasted mice. TG, triglycerides; scale bar = 200 µm; n = 7-
12/group; data are expressed as means ± SD; * P <0.05, ** P <0.01. 
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Discussion 
The present study has characterized the contribution of peripheral insulin-sensitive tissues to 
lipid accumulation in liver upon loss of PTEN. Previous reports proposed that lipid accumulation 
in PTEN-deficient liver is driven by enhanced de novo lipogenesis due to hyperactivated AKT2 
[24,25]. Indeed, deletion of AKT2 was found to inhibit the development of hepatic steatosis in 
mouse models with hepatocyte-specific Pten-deficiency, in leptin-deficient mice and in mice fed 
a high-fat diet [26,39]. However, the accumulation of lipids in the liver might not only depend on 
hepatic AKT2 activity but also on AKT2 activity in peripheral insulin-sensitive tissues via 
systemic interactions. To examine this, we used mice with a whole-body Pten-haplodeficiency, 
which in contrast to previous models have reduced PTEN levels in all tissues, including liver, 
pancreas, adipose tissue and skeletal muscle. Pten
+/-
/Akt2
-/- 
mice were also included in order to 
characterize the role of AKT2 signaling in the accumulation of hepatic lipids in this mouse 
model. 
 
In contrast to hepatic steatosis in mice with hepatocyte-specific Pten-deficiency, we found that 
Pten
+/-
/Akt2
+/+ 
mice have a significantly reduced hepatic lipid content, however, with similarly 
enhanced activation of hepatic AKT signaling [24,26]. Pten
+/-
/Akt2
+/+ 
mice showed significantly 
increased activation of AKT and upregulation of lipogenic genes, but no differences in 
expression of genes involved in -oxidation. The enhanced hepatic insulin signaling we observed 
indicates that extra-hepatic factors prevent accumulation of lipids in the livers of Pten
+/-
/Akt2
+/+ 
mice. To define the factors reducing hepatic lipids in Pten
+/-
/Akt2
+/+ 
mice, we characterized 
pancreatic morphology and insulin signaling in adipose tissue and skeletal muscle. 
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Several lines of evidence suggest that hepatic lipid content of Pten
+/-
/Akt2
+/+ 
mice might be 
affected by PTEN and AKT2 activity in pancreas and adipose tissue. Pancreas-specific deletion 
of Pten leads to hyperplastic pancreatic islets and ductal metaplasia and also improved metabolic 
control and elevated hepatic AKT signaling [40,41]. We found that the exo- and endocrine part 
of the pancreas of Pten
+/-
/Akt2
+/+ 
mice displayed overall normal morphology. Adipocyte-specific 
deletion of Pten was shown to result in hyperactivated AKT and improved glycemic control [42]. 
Enhanced energy expenditure in adipocytes was shown to reduce hepatic lipid content in mice 
[43]. In this study, AKT phosphorylation and expression of genes involved in energy expenditure 
in adipose tissue of Pten
+/-
/Akt2
+/+ 
mice was not changed. Thus, Pten-haplodeficiency in pancreas 
and adipose tissue might have only minor effects on hepatic lipid accumulation. Nevertheless, it 
merits further investigations, preferably using tissue-specific knockout mice, if PTEN and AKT2 
in pancreas, adipose tissue and also other tissues have effects on hepatic metabolism that were 
not detected in this study. 
 
Studies in humans have shown that insulin resistance of skeletal muscle promotes the 
development of NAFLD by redistribution of ingested carbohydrates towards hepatic de novo 
lipogenesis [12,39,44]. Moreover, hepatic lipid content was found to be reduced after insulin 
sensitivity of skeletal muscle was improved by physical exercise [12,39,44]. Another study 
showed that ectopic expression of constitutively active AKT1 in skeletal muscle of mice 
protected against diet-induced hepatic steatosis, by increasing -oxidation in the liver [45]. Our 
results demonstrate an enhanced insulin response of skeletal muscle in Pten
+/-
/Akt2
+/+ 
mice as 
evidenced by increased glycogen content and AKT signaling upon insulin stimulation, which is 
mediated by AKT2. This data indicate that AKT2 in the skeletal muscle of Pten
+/-
/Akt2
+/+ 
mice is 
52 
 
a key factor in the reduction of hepatic lipid accumulation. Indeed, skeletal muscle-specific 
expression of AKT
K180A
 increased hepatic lipid content in Pten
+/-
/Akt2
+/+ 
mice. Hence, these data 
support the hypothesis that an enhanced skeletal muscle insulin response mediated by AKT2 is 
the predominant factor preventing accumulation of lipids in the liver of Pten
+/-
/Akt2
+/+ 
mice. The 
crucial role of skeletal muscular AKT2 in the accumulation of hepatic lipids is further underlined 
by the effects of skeletal muscle-specific expression of myr-AKT2 and AKT2
K180A 
in
 
Pten
+/+
/Akt2
+/+ 
mice, which resulted in reduced and increased hepatic lipid content, respectively. 
 
The expression of lipogenic genes in the liver of Pten
+/-
/Akt2
-/- 
mice was at similarly high levels 
as observed in Pten
+/-
/Akt2
+/+ 
mice, showing that the expression is only partially dependent on 
AKT2 in these mice. This is in line with previous findings showing that the regulation of 
lipogenic genes by AKT2 is context-dependent [24,26,37]. While in mice with hepatocyte-
specific Pten-deficiency and leptin-deficiency the expression of lipogenic genes was found to be 
dependent on AKT2, the expression was not altered in Akt2-deficient mice fed with normal chow 
or a high-fat diet enriched in simple carbohydrates (Surwit diet) [24,26,37]. Activation of AKT2 
in skeletal muscle of Pten
+/-
/Akt2
-/- 
mice is reduced; however, hepatic lipid content is as low as 
observed in Pten
+/-
/Akt2
+/+ 
mice. This supports previous findings indicating that AKT2 is 
required for lipid accumulation in a hepatocyte-autonomous manner [37].  
 
Despite the fact that hepatic de novo lipogenesis is a bona fide insulin response, NAFLD 
frequently occurs in insulin-resistant and diabetic patients. Recent studies have suggested that 
insulin resistance of skeletal muscle is a central factor in the development of NALFD 
[12,39,44,46]. In addition, a model of selective hepatic insulin resistance was proposed that 
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promotes NAFLD development. According to this model insulin fails to inhibit gluconeogenesis 
but still induces hepatic de novo lipogenesis in the liver [11]. Due to steady output of glucose 
from the liver insulin levels remain elevated, which further boosts hepatic de novo lipogenesis 
and accumulation of lipids [11]. The present study shows that hepatic lipid content is low in 
Pten
+/-
/Akt2
+/+
 mice despite increased activation of AKT2 and upregulation of lipogenic genes in 
the liver, and that an enhanced skeletal muscle insulin response reduces the accumulation of 
hepatic lipids. Hence, our data support the model that skeletal muscle insulin resistance is a 
central factor in the development of NAFLD. Thus, improving the insulin response in skeletal 
muscle by exercise and/or insulin sensitizer may be an effective option for treatment of NALFD. 
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Supplementary figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S1. Validation of gene targeting in adipose tissue.  
Protein levels of PTEN, AKT2, AKT1 and pan-AKT in 
adipose tissue. Densitometric quantification is shown. n = 
4/group; data are expressed as means ± SD; * P <0.05; ** P 
<0.01. 
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Figure S2. Overall normal pancreatic morphology in Pten
+/-
/Akt2
+/+
 mice and 
increased -cell mass in Pten+/-/Akt2-/- mice. (A, B, C, D) Representative images of 
H&E-stained pancreatic sections (A) and the relative numbers of islets (B), size 
distribution of islets (C) and islet area (D). (E, F) Representative images of pancreatic 
sections stained for insulin (green), glucagon (red) and DNA (blue) (E), and the 
quantification of -cell size (F). Scale bar = 500 µm; n = 5-8/group; data are 
expressed as means ± SD; * P <0.05. 
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Figure S3. Insulin-induced AKT phosphorylation in adipose tissue is not affected in 
Pten
+/-
/Akt2
+/+
 but is greatly diminished in Pten
+/-
/Akt2
-/-
 mice. (A) Gonadal fat pad to 
body weight ratios. n = 5-9/group (B) Phosphorylation of AKT at S473 and T308 and 
pan-AKT protein levels in adipose tissue of fasted and insulin stimulated mice. 
Densitometric quantification is shown. n = 3-4/group. (C, D, E) Relative mRNA levels of 
lipogenic genes (C), genes involved in -oxidation (D) and genes implicated in energy 
expenditure (E) in adipose tissue of fasted mice. n = 5-8/group. Data are expressed as 
means ± SD; * P <0.05; ** P <0.01. 
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4. General discussion 
Despite extensive efforts the molecular mechanisms of NAFLD development have not been fully 
elucidated. Recently, several components of the insulin signalling pathway such as PTEN, PKBβ 
and mTORC1 were shown to be involved in NAFLD development in a hepatocyte-intrinsic 
manner in mice (81, 82, 108, 109, 120, 122). However, the metabolic state of the liver does not 
merely depend on hepatic insulin response but also on peripheral insulin sensitive tissues via 
systemic interaction. The aim of this thesis was to characterize the effects of systemically 
perturbed PTEN/PKBβ signaling on accumulation of hepatic lipids. To examine this, we used 
mice with a whole-body Pten-haplodeficiency, which in contrast to previous models have 
reduced PTEN levels in all tissues, including liver, pancreas, adipose tissue and skeletal muscle. 
Pten+/-/Pkbβ-/- mice were also included in order to characterize the potential role of PKBβ 
signaling in the accumulation of hepatic lipids in this mouse model. 
 
In this study we found that, in contrast to spontaneous development of hepatic steatosis in mice 
with liver-specific Pten-deficiency, Pten+/-/Pkbβ+/+ mice have significantly reduced hepatic 
lipids. Pten+/-/Pkbβ+/+ livers displayed enhanced activation of PKBβ and upregulation of 
lipogenic genes, indicating that accumulation of lipids in the liver is prevented by extra-hepatic 
factors. Analysis of peripheral tissues suggested that enhanced insulin signaling mediated by 
PKBβ in the skeletal muscle is a key factor in reduction of hepatic lipids. Indeed, skeletal 
muscle-specific expression of constitutively active PKBβ reduces hepatic lipids in 
Pten+/+/Pkbβ+/+ mice and dominant negative PKBβ led to increased hepatic lipid content in both 
Pten+/+Pkbβ+/+ and Pten+/-/Pkbβ+/+ mice. 
 63 
 
Deletion of PKBβ inhibits the development of hepatic steatosis in different mouse models of 
NAFLD (120, 122). Hence it was proposed that inhibition of PKBβ might be an effective target 
for treatment of NAFLD (122). However, systemic or liver-specific inhibition of PKBβ could 
deteriorate glycemic control (113, 118, 122). Our results show that activation of PKBβ in the 
skeletal muscle reduces hepatic lipid content, which can override lipogenic effects of 
hyperactivated PKBβ in the liver. These findings support the notion that skeletal muscle insulin 
resistance is a central factor in the development of NAFLD. Thus, improving the insulin 
response in skeletal muscle by physical exercise and/or skeletal muscle-specific insulin sensitizer 
may be an effective option for treatment of NALFD. Improved skeletal muscle insulin sensitivity 
would also be beneficial for glycemic control in obese and diabetic patients.  
 
Today there is a high demand on novel therapies to counter the rising incidence of obesity, T2D 
and related complications such as cardiovascular disease, diabetic nephropathy and NAFLD 
(43). Lifestyle changes such as healthier diets and physical exercise improve insulin sensitivity 
and are very effective measures for prevention as well as treatment of obesity and T2D (11, 126-
128). Healthier diet, physical exercise and weight loss reduce the risk of T2D progression in 
patients with impaired glucose tolerance by 30-60% (127, 129). In comparison, metformin, a 
widely used glucose lowering drug, reduces the risk of T2D progression by 31% (127). 
Importantly, lifestyle changes were found to have sustained effects (127). While preventive 
effects of glucose lowering drugs cease quickly after their withdrawal, a reduction in the risk of 
T2D progression maintains after lifestyle counseling stopped (36% relative risk reduction 3 years 
post-intervention) (127, 128). Lifestyle changes were also shown to be effective in NALFD 
treatment (34). For instance, 2 weeks of diet and exercise therapy in diabetic patients reduced 
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hepatic lipid content by 27% (34, 130). Weight loss by caloric restriction and physical exercise is 
therefore recommended as first line treatment of NAFLD (131). However, lifestyle changes have 
been proven difficult to achieve (11, 126).  
 
Despite intensive clinical research, there is currently no standard pharmacological treatment for 
NAFLD and NASH. Treatment options of NAFLD and NASH by administration of bile acids, 
vitamin E or insulin sensitizer such as pioglitazone are under investigation (132-135). Vitamin D 
deficiency is increasingly recognized in NAFLD patients (136). In rats, vitamin D deficiency 
worsens NALFD and its supplementation by phototherapy has beneficial effects (136-138). 
Vitamin D administration may ameliorate NAFLD by several mechanisms such as increasing 
adiponectin level, reducing TNFα and IL-6 level and improving insulin sensitivity (136). 
Ongoing clinical trails are investigating the effects of vitamin D supplementation on liver 
histology in NAFLD and NASH patients (139, 140). 
 
Studies in mice have demonstrated that inhibition of effectors and negative regulators of the 
insulin signaling pathway by genetic deletion can protect against genetically- and diet-induced 
obesity, insulin resistance and NAFLD (43). However, systemic modification of insulin signaling 
may have severe adverse effects. Negative regulators such as PTP1b and PTEN do not 
exclusively restrain insulin response but also regulate cell survival, differentiation and 
proliferation downstream of diverse growth factors and environmental stimuli (43). Global 
activation of the insulin signaling pathway by inhibition of PTEN is beneficial for metabolic 
control, but it also leads to cancer development (43). The PI3K/PKB/mTOR signaling pathway is 
inappropriately activated in many types of cancer, promoting growth and survival of cancer cells 
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(141). Thus, inhibitors targeting PI3K, PKB and mTOR are in clinical development and also 
successfully used in cancer therapy such as Everolimus and Temsirolimus in the treatment of 
metastatic renal cell carcinoma (43, 141, 142). Among several adverse effects, these inhibitors 
were found to impair metabolic control. Everolimus and Temsirolimus may cause 
hypercholesterolemia, hypertriglyceridemia and hyperglycemia with the need of subsequent lipid 
and glucose lowering treatments (43, 142). In contrast, tissue-specific inhibition of 
PI3K/PKB/mTOR signaling downstream of insulin can also improve metabolic control as shown 
in mice with adipocyte-specific deletion of Insr or Raptor (69, 87). Hence, the use of PI3K, PKB 
and/or mTOR inhibitors in a tissue-specifc manner might be beneficial for metabolic control. 
Tissue-specific targeting could be achieved by utilizing transmembrane carriers for selective 
cellular drug uptake, antibody-mediated drug delivery, metabolic activation of prodrugs or viral-
mediated gene therapy (43). If adipocyte-specific inhibition of INSR and mTORC1 in humans 
would have effects similar to those observed in mice remains to be elucidated.  
 
The positive effects on metabolic control observed in transgenic mouse models raise the hope for 
novel targeted therapies to treat obesity, T2D and related complications such as NAFLD. 
Understanding the mechanisms of context- and stimuli-specific function of potential targets as 
well as tissue-specific and long-term effects of modified activity will allow the development of 
therapies with minimized adverse effects tailored to individual demands (43).  
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6. Appendix 
6.1. PI3K/AKT, MAPK and AMPK signalling: protein kinases in glucose 
homeostasis. 
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Abstract 
New therapeutic approaches to counter the increasing prevalence of obesity and type 2 diabetes 
mellitus are in high demand. Deregulation of the phosphoinositide-3-kinase (PI3K)/v-akt murine 
thymoma viral oncogene homologue (AKT), mitogen-activated protein kinase (MAPK) and 
AMP-activated protein kinase (AMPK) pathways, which are essential for glucose homeostasis, 
often results in obesity and diabetes. Thus, these pathways should be attractive therapeutic 
targets. However, with the exception of metformin, which is considered to function mainly by 
activating AMPK, no treatment for the metabolic syndrome based on targeting protein kinases 
has yet been developed. By contrast, therapies based on the inhibition of the PI3K/AKT and 
MAPK pathways are already successful in the treatment of diverse cancer types and 
inflammatory diseases. This contradiction prompted us to review the signal transduction 
mechanisms of PI3K/AKT, MAPK and AMPK and their roles in glucose homeostasis, and we 
also discuss current clinical implications. 
 
Abstract taken from (43). 
 
PI3K/AKT, MAPK and AMPK
signalling: protein kinases in
glucose homeostasis
Simon M. Schultze1,2, Brian A. Hemmings2, Markus Niessen1
and Oliver Tschopp1,*
New therapeutic approaches to counter the increasing prevalence of obesity
and type 2 diabetes mellitus are in high demand. Deregulation of the
phosphoinositide-3-kinase (PI3K)/v-akt murine thymoma viral oncogene
homologue (AKT), mitogen-activated protein kinase (MAPK) and AMP-activated
protein kinase (AMPK) pathways, which are essential for glucose homeostasis,
often results in obesity and diabetes. Thus, these pathways should be attractive
therapeutic targets. However, with the exception of metformin, which is
considered to function mainly by activating AMPK, no treatment for the
metabolic syndrome based on targeting protein kinases has yet been
developed. By contrast, therapies based on the inhibition of the PI3K/AKT and
MAPK pathways are already successful in the treatment of diverse cancer types
and inflammatory diseases. This contradiction prompted us to review the signal
transduction mechanisms of PI3K/AKT, MAPK and AMPK and their roles in
glucose homeostasis, and we also discuss current clinical implications.
Metabolic syndrome is generally defined as a
cluster of risk factors for cardiovascular disease
and type 2 diabetes mellitus (T2DM) including
central obesity, arterial hypertension,
dyslipidaemia and elevated fasting glucose
(Ref. 1). Impaired glucose homeostasis, as
observed in patients with metabolic syndrome,
frequently progresses to overt T2DM, which in
2010 affected 344 million patients worldwide
(Ref. 2). Hyperglycaemia in diabetic patients can
lead to life-threatening complications such as
coronary heart disease, stroke and nonalcoholic
fatty liver disease (Refs 3, 4, 5).
Strict control of the level of circulating glucose
within a narrow physiological range supplies
sufficient energy for organs and avoids
hyperglycaemia. Glucose homeostasis is largely
maintained by the insulin–glucagon system,
which compensates for physiological
fluctuations in blood glucose caused by food
intake and physical activity, or by stress
conditions such as hypoxia and inflammation.
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Insulin and glucagon are released from β- and α-
cells, respectively, in the endocrine part of the
pancreas. Insulin lowers blood glucose by
stimulating glucose uptake and storage
(glycogen synthesis and lipogenesis) in skeletal
muscle and adipose tissue. In the liver, insulin
blocks the release and neogenesis of glucose and
stimulates glucose storage. In addition, insulin
stimulates protein synthesis, regulates
mitochondrial biogenesis and blocks autophagy.
Glucagon antagonises the action of insulin,
mostly in the liver, where it stimulates
gluconeogenesis and thereby increases blood
glucose level. The secretion of insulin and
glucagon is regulated in a reciprocal manner,
which avoids glycaemic volatility because of
their opposing effects. It was proposed that the
glucose-induced secretion of insulin inhibits
glucagon secretion from α-cells in a paracrine
manner (Ref. 6). Furthermore, incretin hormones
[e.g. glucagon-like peptide 1 (GLP-1)] secreted
postprandially by the gut potentiate glucose-
mediated insulin secretion and block glucagon
secretion (Ref. 7). In addition, physiological
conditions such as low intracellular energy level
and cellular stress affect whole-body glucose
homeostasis by interfering with insulin action.
Signal transduction from a stimulus to the
regulation of cellular processes, including those
involved in glucose homeostasis, is primarily
dependent on protein kinase signalling. On
activation, protein kinases determine the output
of metabolic processes by transcriptional and
post-translational regulation of rate-limiting
enzymes, such as glycogen synthase 1
(GYS1) and fatty acid synthase (FASN, FAS).
The insulin receptor (INSR, IR) activates
various downstream pathways that control
energy homeostasis, including
phosphoinositide-3-kinase (PI3K)/v-akt murine
thymoma viral oncogene homologue [AKT, also
known as protein kinase B (PKB)] and the
mitogen-activated protein kinase 3/1 (MAPK3/
1, ERK1/2). Whereas the PI3K/AKT pathway is
considered to be the major effector of metabolic
insulin action, insulin-independent kinases also
contribute to metabolic control. AMP-activated
protein kinase (AMPK) is mostly activated by
low intracellular energy levels and inhibits
anabolic processes, stimulates energy-producing
catabolic processes and lowers blood glucose
level. Because correct functioning of the PI3K/
AKT, MAPK and AMPK pathways is essential
for proper metabolic control and their
dysfunction often leads to impaired glucose
homeostasis, these pathways are attractive
therapeutic targets (Refs 8, 9, 10). However,
PI3K/AKT, MAPK and AMPK are also involved
in several other fundamental cellular processes,
including cell proliferation and survival, and
thus global therapeutic modification of their
activities could induce severe side effects.
Today, specific kinase inhibitors are used
successfully for immunosuppression and in the
treatment of inflammatory disease and diverse
cancer types. However, because proper
activation of the PI3K/AKT pathway is required
for insulin action, kinase inhibitors targeting
PI3K/AKT and downstream effectors might
impair metabolic control. Even though
inappropriate activation of MAPKs, especially of
c-Jun N-terminal kinase (MAPK8, JNK), is
considered to have a critical role in acquired
insulin resistance, no therapies based on MAPKs
are available so far. The only drug targeting
protein kinase activity that is widely used today
in the treatment of insulin resistance and
diabetes is metformin, which is thought to
operate mainly by activating AMPK. Although
our understanding of the role of protein kinases
in the regulation of glucose homeostasis has
increased significantly during the past decade,
only limited translation into therapies against
the metabolic syndrome has occurred. The
purpose of this present review is to summarise
the signal transduction mechanisms involving
PI3K/AKT, MAPK and AMPK with respect to
their role in glucose homeostasis and to discuss
current clinical implications.
The PI3K–AKT signalling pathway is the
major effector of metabolic insulin action
Insulin is an indispensable regulator of glucose
homeostasis, and T2DM is characterised by
postreceptor insulin resistance combined with β-
cell failure. Insulin signalling is initiated by the
binding of insulin to the extracellular α-subunits
of the heterotetrameric IR. This interaction
induces conformational changes and facilitates
autophosphorylation of tyrosine residues on
the intracellular part of membrane-spanning
β-subunits. These phosphotyrosines then attract
a family of adaptor molecules, the insulin
receptor substrates (IRSs). On interaction with
the IR, IRS proteins themselves are tyrosine
phosphorylated, which is partially mediated by
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the tyrosine kinase activity of the IR and also
by other kinases. Once phosphorylated, IRS
proteins attract downstream signalling
molecules, thereby linking the activated IR to
the various downstream signalling pathways
(Ref. 11).
Molecular mechanism of the PI3K/AKT
signalling pathway downstream of insulin
The PI3K/AKT pathway is required for insulin-
dependent regulation of systemic and cellular
metabolism (Ref. 8). Besides insulin, many other
growth factors, cytokines and environmental
stresses can activate PI3K/AKT, mainly in the
regulation of cell proliferation, motility,
differentiation and survival (Ref. 12). Thus,
PI3K/AKT action is highly context dependent,
which is at least partially mediated by the
recruitment of different isoforms of PI3K
(including p85α, p110α, p110β) and AKT
(AKT1, AKT2, AKT3) downstream of individual
stimuli (Refs 13, 14, 15). The AKT isoforms are
encoded by individual genes located on
different chromosomes, share approximately
80% identity in their amino acid sequences and
form the same protein structure, including an N-
terminal pleckstrin homology (PH), a catalytic
domain and a C-terminal regulatory domain
(Ref. 16). Among the AKT isoforms, AKT2 is
considered to be the major isoform required for
metabolic insulin action. Although intensively
investigated, the exact molecular mechanisms
underlying isoform and context specificity are
still not fully elucidated. Here we focus on the
function of the PI3K/AKT pathway downstream
of IR and IRS proteins and its role in glucose
homeostasis.
The PI3K/AKT pathway is activated
downstream of the IR by binding an SH2
domain within the regulatory subunit of PI3K
(p85) to phosphotyrosines in IRS1/2. This leads
to recruitment and activation of the catalytic
subunit of PI3K (p110). Once activated, PI3K
converts phosphatidylinositol-4,5-bisphosphate
(PIP2) to phosphatidylinositol-3,4,5-triphosphate
(PIP3) at the plasma membrane. AKT binds
through its PH domain to PIP3, which facilitates
activation of AKT by upstream kinases. Initially,
3-phosphoinositide-dependent protein kinase-1
(PDPK1, PDK1) induces about 10% of kinase
activity by phosphorylating Thr308 in the
catalytic domain of AKT. Subsequently,
mammalian target of rapamycin complex 2
(mTORC2), DNA-dependent protein kinase
(DNA-PK) and ataxia telangiectasia mutated
kinase (ATM) induce full kinase activity of AKT
by phosphorylating Ser473 in the regulatory
domain. Although DNA-PK can phosphorylate
AKT at Ser473 on insulin stimulation in vitro, it
is thought to activate AKT in vivo mainly
following stress such as DNA damage (Refs 17,
18, 19). mTORC2 is considered to be the
predominant AKT Ser473 kinase downstream of
insulin and growth factor stimuli (Ref. 18). On
activation, AKT is released from the plasma
membrane and translocates to cellular
compartments, such as the cytoplasm,
mitochondria and nucleus, where it
phosphorylates its many substrates. Substrates
implicated in the regulation of cellular
metabolism include glycogen synthase kinase 3β
(GSK3β), forkhead box protein O1 (FOXO1) and
AKT substrate 160 (TBC1D4, AS160), which
regulate glycogen synthesis, gluconeogenesis
and glucose uptake, respectively. AKT also
activates mTORC1 by inhibiting tuberous
sclerosis complex 1/2 (TSC1/2). Activated
mTORC1 upregulates mitochondrial biogenesis,
inhibits autophagy and induces protein
synthesis by regulation of peroxisome
proliferator-activated receptor gamma
coactivator 1α (PGC1α), unc-51-like kinase 1
(ULK1), and ribosomal protein S6 kinase (S6K)
and eIF4E-binding protein 1 (4E-BP1),
respectively. PDK1 also activates isoforms of
protein kinase C (PKCλ/ζ), which are required
for Glut4-dependent regulation of glucose
uptake. Moreover, AKT and PKCλ/ζ control de
novo lipogenesis by regulating lipogenic genes,
such as sterol regulatory element-binding
transcription factor 1 (SREBF1, SREBP1c) and
peroxisome proliferator-activated receptor γ
(PPARγ) (Refs 20, 21). The mechanisms by
which AKT and PKCλ/ζ regulate lipogenic
genes are not yet completely understood.
The insulin–PI3K/AKT pathway is negatively
regulated at different levels. Phosphatases,
including protein tyrosine phosphatase
nonreceptor type 1 (PTPN1, PTP1B),
phosphatase and tensin homologue (PTEN)
and protein phosphatase 2A (PP2A),
dephosphorylate and thereby inhibit IR, IRS1/2,
PIP3 and AKT, respectively. AKT activity can
also be inhibited by binding partners, such as
thioesterase superfamily member 4 (THEM4,
CTMP) and tribbles homologue 3 Drosophila
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(TRIB3) (Refs 22, 23).Whereas the function ofmost
AKT-binding partners in glucose homeostasis
remains to be elucidated, TRIB3 was shown to
inhibit insulin signalling (Ref. 23). Furthermore,
negative-feedback loops are implemented in the
PI3K/AKT pathway that downregulate insulin
signalling. GSK3β, mTORC1 and S6K can
phosphorylate IRS on serine residues, which can
lead to their ubiquitylation and proteolytic
breakdown (reviewed in Refs 12, 24, 25) (Fig. 1).
Genetic alterations in components of the
insulin signalling pathway can impair or
improve metabolic control
Many studies have been carried out in mice and
humans and have been pivotal in defining the
molecular events underlying insulin signalling.
Most patients develop insulin resistance and
T2DM as a result of polygenetic predisposition
in combination with overnutrition and obesity
(acquired insulin resistance). Monogenetic
defects causing diabetes account for only 1–5%
of cases and have been found in loci encoding
elements of the insulin signalling pathway,
transcription factors and rate-limiting enzymes
of glucose metabolism (e.g. hepatocyte nuclear
factor 4α and glucokinase) and also in
mitochondrial genes (Ref. 26). Interestingly, both
enhancement of insulin signalling by deletion of
negative regulators and specific interference
with its action by deleting targets normally
activated by insulin can improve metabolic
control and protect against diabetes in mice.
From IR to AKT: genetic mutations and
their effects on insulin sensitivity
in humans and mice
Patients with loss-of-function mutations in IR are
severely insulin resistant and display signs of
hyperglycaemia and hyperinsulinaemia, thus
indicating that IR is essential for insulin action
(Refs 27, 28, 29). Experiments in vitro have
confirmed that amino acid substitutions in the
tyrosine kinase domain of IR found in patients,
such as glycine (G) to valine (V) at position 996
(G996V) and Q1131R, indeed block insulin
signalling, as shown by markedly reduced IR
tyrosine kinase activity and diminished
phosphorylation of IRS1/2 (Refs 28, 30).
Of the postreceptor gene mutations in the
insulin signalling cascade, only a few were
found to cause severe insulin resistance in
humans. Several variants of IRS1 and IRS2 have
been identified in patients with insulin
resistance. Two IRS1 variants, a common
(G972R) and a rare (T608R) polymorphism, were
associated with reduced insulin sensitivity in
obese men and severe insulin resistance,
respectively (Refs 31, 32). Both polymorphisms
are located in regions implicated in PI3K
binding and abolished insulin-stimulated PI3K
activity in cell culture models (Refs 32, 33). By
contrast, variants of IRS2 were not associated
with insulin resistance, and their biochemical
properties were not characterised (Refs 34, 35).
Of the known polymorphisms in p85α and
p110β subunits of PI3K, only an R409Q amino
acid substitution in p85α was shown to
compromise insulin-stimulated PI3K activity
(Refs 36, 37). Remarkably, a mutation identified
in AKT2 resulting in an R274H amino acid
substitution in the kinase domain was
associated with autosomal dominant inherited
severe insulin resistance. AKT2 R274H has
greatly reduced kinase activity and acts in a
dominant-negative manner in that its
overexpression blocks the inhibition of FOXA2
in HepG2 cells and impairs adipocyte
differentiation in vitro (Ref. 38).
Findings in transgenic mice complement the
above observations. Mice deficient in the IR
develop severe hyperglycaemia within hours
after birth and die within days as a result of
severe ketoacidosis (Refs 39, 40). IRS1-deficient
mice have peripheral insulin resistance, but
show only slight hyperglycaemia because of
compensatory hyperinsulinaemia (Refs 41, 42).
A more severe metabolic phenotype was
observed in mice deficient in IRS2. These
animals are also insulin resistant, but show
hyperglycaemia as a result of impaired
adaptation of β-cell mass (Ref. 43). By contrast,
specific loss of elements of insulin signalling can
also improve metabolic control. It was shown
that mice with an adipose-tissue-specific
deletion of Ir are protected against obesity and
obesity-related insulin resistance (Ref. 44).
Whereas p85α R409Q is associated with reduced
insulin sensitivity in humans, loss of p85α by
mutation of the corresponding gene Pik3r1
(which encodes p85α, p55α and p50α) resulted
in improved glucose tolerance and
hypoglycaemia in mice (Refs 45, 46). It was
suggested that the loss of p85α is compensated
by p50α, which generated an increase in PIP3
on insulin stimulation (Ref. 45). However, there
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may be further compensatory mechanisms, given
that mice lacking all three isoforms of Pik3r1 are
also hypoglycaemic (Ref. 46). These studies
demonstrate that ablation of proteins can have
effects different from loss-of-function mutations
and also from inhibitor treatments in which the
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Figure 1. Simplified view of insulin-stimulated PI3K/AKTsignalling and its substrates involved in cellular
metabolism. A detailed description is given in the text. Abbreviations: ACACA, ACC, acetyl-CoA carboxylase;
AKT, v-akt murine thymoma viral oncogene homologue 1; 4E-BP1, eIF4E-binding protein 1; FOXO1, forkhead
box O1; G6Pase, glucose-6-phosphatase; GSK3β, glycogen synthase kinase 3β; GYS1, glycogen synthase;
INSR, IR, insulin receptor; IRS1/2, insulin receptor substrates 1/2; ME1, malic enzyme 1; mTORC1,
mammalian target of rapamycin complex 1; mTORC2, mTOR complex 2; PDPK1, PDK1,
3-phosphoinositide-dependent protein kinase-1; PGC1α, peroxisome proliferator-activated receptor
gamma, coactivator 1α; PI3K, phosphoinositide-3-kinase; PIP2, phosphatidylinositol-4,5-bisphosphate;
PIP3, phosphatidylinositol-3,4,5-triphosphate; PKC1, PEPCK, phosphoenolpyruvate carboxykinase 1;
PKCλ/ζ, protein kinase Cλ/ζ; PPARγ, peroxisome proliferator-activated receptor g; PP2A, protein
phosphatase 2A; PTPN1, PTP1b, protein tyrosine phosphatase, non-receptor type 1; RPS6, S6, ribosomal
protein S6; SCD, stearoyl-CoA desaturase; S6K, ribosomal protein S6 kinase; SLC2A4, GLUT4, solute
carrier family 2; SREBF1, SREBP1-c, sterol regulatory element binding transcription factor 1; TBC1D4,
AS160, AKT substrate 160; TRIB3, tribbles homologue 3; TSC1/2, tuberous sclerosis complex 1/2; ULK1,
unc-51-like kinase 1.
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inoperative protein remains present. For detailed
descriptions of these mouse models, the reader
is referred to another review (Ref. 47).
As described above, loss-of-function mutations
in genes of the insulin signalling pathway mostly
reduce insulin sensitivity to varying degrees.
These findings support the notion that these
genes are required for insulin action and are the
basis of our understanding of the molecular
mechanisms underlying insulin signalling and
the development of diabetes. Thus, at first sight,
it appears desirable to enhance insulin signalling
in order to counteract the development of
diabetes. However, the observation that adipose-
tissue-specific IR deficiency can improve
metabolic control and protect against obesity
suggests an interesting alternative.
Diverse effects on glucose homeostasis are
observed after deletion of individual AKT
isoforms and downstream protein kinases
in mice
Themechanismsof insulin signalling at the level of
and downstream of, AKT isoforms have been
studied extensively in transgenic mouse models.
AKT1 and AKT2 are ubiquitously expressed,
with high levels in classical insulin target tissues
such as the liver, skeletal muscle and adipose
tissue (Refs 48, 49). By contrast, the expression
of AKT3 appears more restricted and is found
mainly in the brain, the testis, adipose
tissue and pancreatic islets (Refs 48, 49). As in
the case of humans, mice lacking AKT2
are insulin resistant, hyperglycaemic and
hyperinsulineamic (Refs 8, 48, 50). Deficiency in
AKT3 does not result in metabolic aberrations.
However, somewhat conflicting results have
been obtained with mice deficient in AKT1. Two
studies reported no role for AKT1; however, a
third study described higher insulin sensitivity
and improved metabolic control (Refs 48, 51,
52). The molecular mechanisms underlying this
improved insulin sensitivity in AKT1-deficient
mice have not been defined. Although highly
similar in structure, loss of individual
AKT isoforms results in distinct phenotypes,
indicating that AKT isoforms exert
nonredundant functions. This can be partially
explained by divergent expression patterns, but
we are far from understanding the molecular
mechanisms underlying specificity (Ref. 15).
The results obtained in mouse models indicate
that individual downstream effectors of AKT
exert distinct and tissue-specific functions.
GSK3β inhibits glycogen synthesis by
phosphorylating GYS1 and is negatively
regulated by AKT. Accordingly, mice with
specific deletion of Gsk3b in skeletal muscle but
not in the liver showed improved glucose
tolerance owing to enhanced GYS1 activity and
glycogen deposition (Ref. 53). Additionally, it
was shown that mice with a pancreatic β-cell-
specific deletion of Gsk3b display increased
β-cell mass and improved glucose tolerance and
are protected against genetically and diet-
induced diabetes. This increase in β-cell mass
might occur as a result of loss of GSK3β-
mediated feedback inhibition of insulin
signalling, which is known to increase β-cell
proliferation (Refs 54, 55).
mTORC1 and its downstream target S6K are
indirectly activated by AKT2, and their roles
have also been studied in mice. Activation of
mTORC1 in β-cells by deletion of Tsc1 or Tsc2
increased cell size, proliferation and insulin
production. Thus, β-cell-specific activation of
mTORC1 improved glucose-stimulated insulin
secretion and glucose tolerance in mice (Refs 56,
57). Conversely, mice with a whole-body S6K
deficiency showed reduced β-cell mass and
hypoinsulinaemia (Ref. 58). Ablation of
mTORC1 activity in skeletal muscle in mice by
deletion of Raptor reduced oxidative capacity by
the downregulation of genes involved in
mitochondrial biogenesis. Moreover, the
glycogen content of the muscle in these mice
was increased, most likely because of enhanced
inhibition of GSK3β by hyperactivated AKT. As
a result, these mice suffered from progressive
muscle dystrophy and were glucose intolerant
(Ref. 59). Interestingly, mice with an adipocyte-
specific mTORC1 deficiency as well as those
with a whole-body S6K deficiency were
protected against diet-induced obesity and
insulin resistance. The authors proposed that the
protective effects are based on increased energy
expenditure and enhanced insulin signalling,
which are probably due to loss of negative
feedback regulation in adipose tissue (Refs 60,
61). Recently, it was shown that mice with liver-
specific activation of mTORC1 by deletion of
Tsc1 are glucose intolerant but, are protected
against diet-induced hepatic steatosis. The
authors also showed that inhibition of mTOR by
rapamycin does not reduce hepatic lipid
accumulation in mice fed a high-fat diet. Thus, it
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was concluded that mTORC1 is not required and
not sufficient to increase hepatic lipids, but rather
protects against diet-induced hepatic steatosis by
enhancing fat utilisation and gluconeogenesis in
the liver (Ref. 62) (Table 1).
These findings show that not onlyAKT isoforms
but also their downstream effectors perform
distinct functions in the regulation of glucose
homeostasis. Moreover, the impact on metabolic
control of modulating the activity of
downstream components in the insulin
signalling cascade largely depends on the
targeted tissue, as demonstrated in the case of
mTORC1 and S6K. Thus, the development of
techniques for tissue-specific, but not systemic,
targeting of downstream components could
allow further adaption of current therapies to
individual demands, such as improving β-cell
function, reducing hepatic lipid content and
restoring insulin response in skeletal muscle.
Improved glucose homeostasis in mice
lacking negative regulators of PI3K/AKT
Asmentioned above, phosphatases such as PTP1B
and PTEN antagonise insulin signalling. PTP1B
downregulates insulin-stimulated PI3K/AKT
signalling by dephosphorylating IR and IRS1/2
in a more specific manner than PTEN, which
inhibits PI3K/AKT signalling by
dephosphorylating PIP3. Because several other
growth factors, such as EGF and PDGF, can also
increase levels of PIP3 by stimulating PI3K,
PTEN appears to be a critical antagonist of all
PI3K-dependent AKT stimuli. Notably, both
PTP1B deficiency and Pten hemizygosity result
in improved glucose tolerance and insulin
sensitivity in mice (Refs 63, 64). Similar
phenotypes were found in mice with tissue-
specific PTP1B deficiency in muscle or liver, and
PTEN deficiency in muscle, adipose tissue or
liver (Refs 65, 66, 67, 68, 69, 70). Furthermore, it
was shown that mice with whole-body and
muscle-specific PTP1B deficiency, and mice
lacking PTEN in muscle and pancreas, are
protected against diet-induced insulin resistance
(Refs 63, 65, 67, 71). In contrast to PTP1B-
deficient mice, mice with Pten hemizygosity and
mice with PTEN deficiency in hepatocytes
develop tumours in various organs or
progressive hepatic steatosis with the
development of liver cancer, respectively
(Refs 69, 70, 72) (Table 2). These phenotypes
indicate that PTEN is required to control
growth-factor-stimulated PI3K/AKT signalling.
Moreover, PTEN was shown to have a
phosphatase-independent tumour-suppressive
function in the nucleus, which might also have a
role in tumour development in mice (Ref. 73).
Recent evidence suggests that the targeting of
negative regulators further downstream, such as
TRIB3, might enhance insulin signalling without
global activation of the PI3K/AKT pathway.
Whereas mice with whole-body TRIB3
deficiency showed no alterations in metabolic
control under normal conditions, TRIB3 was
shown to be upregulated in the liver of diabetic
mice and hepatic overexpression of TRIB3
impaired glucose tolerance (Refs 23, 74, 75).
Because TRIB3 seems to be dispensable under
normal conditions, but seems to contribute to
obesity-induced insulin resistance, it might
represent an attractive therapeutic target.
As underlined by the complex phenotype of
PTEN-deficient mice, the inhibition of negative
regulators can lead to global activation of
PI3K/AKT with severe side effects such as
hepatic steatosis and cancer. Thus, the safe
targeting of negative regulators of insulin
signalling may be out of reach until the
regulation of context-specific stimulation is
understood. The targeting of negative regulators
further downstream, such as TRIB3, could be
more specific and have improved side-effect
profiles.
mTOR inhibitors in clinical use and how
they affect glucose homeostasis
Although results from the studies described above
show that interfering with PI3K/AKT/mTOR
signalling mostly leads to insulin resistance, its
inhibition is an attractive treatment option for
various other diseases. Inhibition of PI3K/
AKT/mTOR signalling should be considered
especially in cancer therapy, because
inappropriate activation of this pathway is
frequently observed in many tumour types.
Indeed, the mTOR inhibitors temsirolimus and
everolimus have been approved for the treatment
of metastatic renal cell carcinoma (mRCC) and
improve overall or progression-free survival
(Refs 76, 77). Current trials explore the efficiency
of mTOR inhibitors when used in combination
with other therapies, including small-molecule
tyrosine kinase inhibitors or VEGF-directed
antibodies (Ref. 78). In addition to mRCC, an
increasing number of clinical trials study the
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Table 1. Overview of mouse models for AKT isoforms and downstream targets
Gene Deleted in Insulin
sensitivity
Glucose
tolerance
Further characteristics Refs
Akt1 Whole body + + Reduced body size, increased
neonatal mortality
48,
49
Akt2 Whole body − − Diabetes-like phenotype with
compensatory increase in
pancreatic β-cell mass, protected
against genetic- and diet-induced
hepatic steatosis
8, 20,
48,
50,
159
Hepatocytes NR NR Protected against genetic- and diet-
induced hepatic steatosis
20
Akt3 Whole body UC UC Impaired postnatal brain
development, no obvious metabolic
phenotype
48,
160
Gsk3a Whole body + + Increased hepatic glycogen content,
reduced adipose tissue mass
161
Gsk3b Whole body
(−/−)
NR NR Embryonic lethal 55
Whole body
(+/−)
NR NR Ameliorates genetically induced
diabetes
55
Pancreatic
β-cells
NR + Increased pancreatic β-cell mass,
protected against diet-induced
diabetes
54
Hepatocytes UC UC No distinct metabolic phenotype 53
Skeletal
muscle
+ + Increased muscle glycogen content 53
Tsc1 Pancreatic
β-cells
− + Increased pancreatic β-cell mass,
improvedglycaemic control in young
mice, obesity in old mice
56
Hepatocytes − − Protected against diet-induced
hepatic steatosis
62
Tsc2 Pancreatic
β-cells
NR + Increased pancreatic β-cell mass 57
Raptor Skeletal
muscle
NR − Increasedmuscle glycogen content,
progressive muscle dystrophy
59
Adipose
tissue
NR + Protected against diet-induced
obesity and hypercholesterolaemia
60
S6k Whole body + − Reduced pancreatic β-cell mass,
hypoinsulinaemia, protected against
age- and diet-induced obesity and
insulin resistance
58,
61
Further descriptions are given in the text. NR, not reported; UC, unchanged; +, improved; −, reduced; (−/−),
homozygous mutant; (+/−), heterozygous mutant.
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effects ofmTOR inhibition in other diseases, such as
pancreatic neuroendocrine tumours, astrocytomas,
lymphangioleiomyomatosis and autosomal
dominant polycystic kidney disease (Refs 79, 80,
81, 82, 83, 84). Owing to their inhibitory effect on
proliferation of lymphocytes, both compounds
have also been used for immunosuppression after
transplantation.
However, several side effects have been reported,
such as myelosuppression, pulmonary toxicity and
metabolic disturbances (Refs 85, 86). Treatment
of mRCC with mTOR inhibitors was associated
with increased blood glucose levels,
hypertriglyceridaemia and hypercholesterolaemia
(Refs 76, 77). Similarly, the use of mTOR
inhibitors after kidney transplantation was linked
to elevated cholesterol and triglyceride levels
compared with other immunosuppressive
regimens and, thus, the subsequent need for
lipid-lowering therapy (Ref. 87). Diabetes mellitus
is a frequent complication after solid organ
transplantation with an increased risk of
graft failure and cardiovascular mortality.
Whereas immunosuppressive treatments with
glucocorticoids and calcineurin inhibitors are
known to result in insulin resistance and
impaired insulin secretion, respectively, the role of
mTOR inhibitors in the development of diabetes
after transplantation is more controversial
(Refs 88, 89). Some studies indicate an
independent association of mTOR inhibitors with
diabetes onset after transplantation, but others
didnot come to the sameconclusion (Refs90, 91, 92).
Although mTOR inhibitors have been
implemented successfully in different clinical
settings, they may only be used in the treatment
Table 2. Overview of mouse models for the role of Pten and Ptp1b in glucose
homeostasis
Gene Deleted in Insulin
sensitivity
Glucose
tolerance
Further characteristics Refs
Pten Whole body
(−/−)
NR NR Embryonic lethal 64
Whole body
(+/−)
+ + Protected against genetically
induced diabetes, spontaneous
tumour development
64,
72,
162
Pancreatic
β-cells
NR NR Hypoglycaemia,
hypoinsulinaemia, protected
against streptozotocin- and diet-
induced diabetes
71
Skeletal
muscle
UC + Protected against diet-induced
insulin resistance and diabetes
67
Adipose
tissue
+ + Resistant to streptozotocin-
induced diabetes
68
Hepatocytes NR + Age-dependent hepatic steatosis
and its progressive forms
69, 70
Ptp1b Whole body + + Protected against diet-induced
diabetes
63
Skeletal
muscle
+ + Protected against diet-induced
insulin resistance
65
Hepatocytes + + Reduced hepatic lipid content
after 5 weeks of a high-fat diet,
protected against diet-induced
insulin resistance
66
UC, unchanged; +, improved; −, reduced; (−/−), homozygous mutant; (+/−), hemizygous.
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of specific tumour types, and their efficacy might
be limited by cellular escape mechanisms such as
rapamycin resistance (Ref. 77). Targeting multiple
components of the PI3K/AKT pathway might
improve antitumour potency and broaden the
spectrum of susceptible tumour types. Indeed,
based on structural similarities of PI3K and
mTOR, newly developed inhibitors aimed at
inhibition of both kinases simultaneously are
currently under investigation. In addition to
dual PI3K–mTOR inhibitors, selective AKT
inhibitors are being tested in xenograft mouse
models and early Phase I studies. However,
inhibitors targeting multiple components might
also have more severe side effects with regard to
metabolic control. The use of techniques such as
antibody-directed drug delivery could allow
cell-type-specific targeting of the PI3K/AKT
pathway and thus minimise side effects.
Stress response and MAPK signalling
in acquired insulin resistance
Although at the core of the problem there is still no
satisfying answer to the question of how insulin
resistance develops, a widely discussed concept
involves Ser/Thr kinases, which can
phosphorylate numerous sites in IRS1 and IRS2.
Phosphorylation of IRS proteins on Ser/Thr
residues can uncouple the activated IR from
downstream signal transduction modules
(reviewed in Ref. 93). This phenomenon
potentially depends on three different
mechanisms: prevention of docking of IRS to IR,
ubiquitylation followed by the proteolytic
breakdown of IRS, or prevention of the docking
of downstream effectors such as PI3K. Whereas
in the former two cases all insulin-induced
effects could be abolished, more selective defects
might develop in the latter case, dependent on
which modules are uncoupled from the
activated IR. Multiple negative inputs converge
at the level of IRS proteins. Of major importance
appears to be the increased secretion of
proinflammatory cytokines from adipocytes as
observed in obesity. Proinflammatory signalling
often involves activation of the inhibitor of κ
light polypeptide gene enhancer in B-cells,
kinase (IKBKB, IKK)–NF-κB axis, which is now
regarded as a critical pathway linking obesity-
associated chronic inflammation with insulin
resistance. For example, tumour necrosis factor-
dependent downregulation of IRS proteins
depends on IKK and can be inhibited by aspirin
(Ref. 94). Indeed, that salicylate can increase
insulin sensitivity is an old observation (Ref. 95).
Whereas IKK-knockout mice are embryonic
lethal, mice with IKK hemizygosity show lower
fasting blood glucose and insulin levels and
improved free fatty acid levels relative to
littermate controls when placed on a high-fat
diet or rendered leptin deficient (Ref. 96).
Furthermore, it has been shown that adipocyte-
derived factors can act through IKK to induce
insulin resistance in skeletal muscle (Ref. 97).
In addition to inflammation, the activation of
Ser/Thr kinases with concomitant
downregulation of the function of IRS proteins
has been observed downstream of various
conditions known to be associated with the
development of insulin resistance and T2DM,
such as hypoxia, endoplasmic reticulum (ER)
stress and the generation of reactive oxygen
species. Kinases activated under these conditions
are also called stress kinases, because their
activity positively correlates with the occurrence
of imbalances in cellular homeostasis. An increase
in circulating cytokines, as observed under
systemic low-level inflammation during obesity,
can also activate IRS Ser/Thr kinases (Ref. 93).
Among the kinases targeting IRS are GSK3, S6K,
p38 and several isoforms of the PKC family. The
PKC family consists of 12 isoforms grouped as
atypical PKCs (ζ and λ), conventional PKCs (α, β
and γ), novel PKCs (δ, e, η and θ), and protein
kinase Ns (PKN1, PKN2 and PKN3), from which
PKCδ, PKCλ/ζ and PKCθ are known to target
IRS. One widely discussed case is the activation
of JNK downstream of ER stress and the
unfolded protein response (Refs 98, 99). Obese
humans and rodents develop ER stress in
hepatocytes and adipocytes, leading to JNK-
dependent phosphorylation of IRS1 on Ser307
(numbering as in mouse) (Ref. 100) followed by
its ubiquitylation and proteolytic breakdown.
Indeed, global or conditional loss of JNK in
adipose tissue, skeletal muscle or the brain was
found to attenuate diet-induced insulin resistance
in mice fed a high-fat diet, supporting the notion
of a repressive role for JNK in insulin action
(Ref. 9). Surprisingly, mice in which the target site
for JNK in IRS1 (Ser307) was replaced by an
alanine were less insulin sensitive, as were mice
lacking JNK1 in hepatocytes (Refs 9, 101). The
latter two observations indicate that JNK is
required for insulin action in hepatocytes, once
more underlining the context dependence of
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insulin signal transduction. The case of JNK
exemplifies the dilemma: a significant number of
IRS kinases believed to be responsible for the
development of insulin resistance are also
required for insulin-dependent metabolic control.
For example, ERK1/2 are believed to link insulin
with cell proliferation, differentiation and the
regulation of lipid metabolism, whereas isoforms
of PKC may be required for insulin-induced
glucose transport (Refs 102, 103, 104, 105, 106,
107, 108, 109). These intricate interconnections
certainly complicate the development of
intervention strategies based on MAPKs in the
treatment of insulin resistance.
AMPK – an energy sensor targeted in the
treatment of metabolic syndrome
When intracellular energy levels are low, cellular
metabolism must shift from energy-consuming
anabolic processes towards energy-producing
catabolic processes. AMPK, a sensor of the
availability of intracellular energy, is activated at
low energy levels and regulates cellular
processes accordingly. This kinase inhibits
insulin-stimulated anabolic processes such as de
novo lipogenesis and glycogen synthesis.
Nevertheless, AMPK activity supports whole-
body glucose homeostasis and improves insulin
sensitivity by promoting processes such as
glucose uptake and energy expenditure. The
effects of the widely used antidiabetic drug
metformin have been shown to depend largely
on activation of AMPK (Ref. 110). Thus, AMPK
is currently the only protein kinase targeted in
the treatment of metabolic syndrome.
AMPK signalling pathway
AMPK is a heterotrimeric complex consisting of a
catalytic α-subunit and two regulatory subunits (β
and γ). There are several isoforms of each subunit
encoded by individual genes, including PRKAA1
(α1), PRKAA2 (α2), PRKAB1 (β1), PRKAB2 (β2),
PRKAG1 (γ1), PRKAG2 (γ2) and PRKAG3 (γ3)
(Ref. 111). The different isoforms of AMPK
subunits are expressed tissue specifically and
exert both overlapping and distinct functions
(Refs 112, 113). The AMPK pathway is activated
by a variety of physiological stimuli, such as
glucose deprivation, hypoxia, oxidative stress
and muscle contraction. The common result of
these stimuli is a reduction in cellular energy
level and an increase in AMP/ATP ratio, which
is crucial for AMPK activity. AMPK is also
activated by different hormones, including
leptin and adiponectin, but the mechanisms by
which these hormones activate AMPK are not
yet fully elucidated. For full kinase activity,
AMPK must be phosphorylated at Thr172 in the
catalytic domain of the α-subunit by upstream
kinases such as serine/threonine kinase 11
(STK11, LKB1) and calcium/calmodulin-
dependent protein kinase kinase β (CAMKKβ).
LKB1 is a constitutively active kinase and
considered to be the predominant upstream
kinase of AMPK, but also phosphorylates 13
other AMPK-related kinases (Ref. 114). Protein
phosphatases (PP2A and PP2C) antagonise
upstream kinases and inhibit AMPK activity by
dephosphorylation of Thr172. Most importantly,
AMPK activity and Thr172 phosphorylation are
highly dependent on the intracellular AMP/ATP
ratio. AMP and ATP bind to the γ-subunit of
AMPK in a competitive manner. When the
AMP/ATP ratio is high, binding of AMP to
AMPK allosterically activates kinase activity
fivefold and induces conformational changes
that block the dephosphorylation of Thr172 by
PP2A and PP2C, which preserves activation by
upstream kinases (reviewed in Refs 111, 115,
116). It has been recently proposed that binding
of AMP triggers exposure of a myristoyl group
at the AMPK β-subunit, which promotes
membrane association and primes AMPK for
activation by upstream kinases (Ref. 117). In
addition, it was shown that binding of ADP to
AMPK protects against dephosphorylation of
Thr172, but does not induce allosteric activation
of AMPK (Ref. 118). Activated AMPK
phosphorylates substrates such as AS160, GYS1,
acetyl-CoA carboxylase α (ACACA, ACC) and
malonyl-CoA decarboxylase (MLYCD, MCD),
thus stimulating glucose uptake, inhibiting
glycogen synthesis, inhibiting de novo
lipogenesis and enhancing β-oxidation,
respectively. AMPK also indirectly inhibits
mTORC1, thereby blocking protein synthesis,
enhancing respiration and probably improving
insulin sensitivity by counteracting mTORC1-
and S6K-induced inhibition of IRS1/2 (reviewed
in Ref. 116).
Complex role of AMPK isoforms
in metabolic control
As mentioned above, the antidiabetic effects of
metformin largely depend on AMPK activation.
Thus, characterising the role of AMPK isoforms
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in mammalian physiology is of great importance
and a prerequisite for the achievement of more
specific and efficient targeting of AMPK
compared with metformin. Genetic mutations in
elements of the AMPK pathway in humans and
their pathophysiological effects in glucose
homeostasis are not yet fully characterised.
Several polymorphisms in LKB1 and AMPK α2
and γ2 subunits are associated with insulin
resistance and T2DM in different subsets of
patients (Refs 119, 120, 121). Interestingly,
polymorphisms in LKB1, α1-, α2- and β2-
subunits of AMPK as well as in AMPK targets
myocyte enhancer factor 2A (MEF2A) and
MEF2D were found to be associated with
reduced response to metformin treatment
(Refs 119, 121). Because metformin is thought to
function mainly by activating AMPK, the
identified polymorphisms might affect the
functions of LKB1, AMPK, MEF2A and MEF2D.
However, the physiological and biochemical
consequences of the identified polymorphisms
remain to be characterised. Apart from that,
LKB1 has tumour suppressor functions and its
mutation can cause Peutz–Jeghers syndrome,
which is characterised by mucocutaneous
pigmentation, hamartomatous polyps
and increased risk of cancer (Ref. 122). In
addition, mutations in PRKAG2 were shown to
cause hypertrophic cardiomyopathy with
Wolff–Parkinson–White syndrome owing to a
glycogen storage disorder (Refs 123, 124, 125).
The complex roles of AMPK isoforms in insulin-
sensitive tissues have been studied in transgenic
mice. Whereas loss of AMPKα1 did not alter
metabolic control in mice, global or tissue-
specific loss of individual AMPK isoforms
mostly led to impaired glucose homeostasis
(Ref. 126). PRKAα2-knockout mice were glucose
intolerant and insulin resistant and showed
impaired glucose uptake on stimulation with the
AMPK activator 5-aminoimidazole-4-
carboxamide riboside (AICAR) (Refs 10, 126). In
addition, deletion of Prkaa2 specifically in β-cells
resulted in defective glucose-stimulated insulin
secretion (Ref. 127). Hepatocyte-specific deletion
of Prkaa2 in the liver revealed that AMPK
inhibits gluconeogenesis and release of glucose
in the liver (Ref. 128). PRKAβ2-knockout mice
had reduced maximal and endurance exercise
capacities and were more susceptible to diet-
induced weight gain and glucose intolerance;
PRKAγ3-knockout mice were shown to have
impaired AICAR-stimulated glucose uptake
(Refs 129, 130). By contrast, activation of AMPK
in the hypothalamus increased food intake,
suggesting that inhibition of AMPK in the
hypothalamus could protect against obesity-
induced insulin resistance (Ref. 131). Indeed,
mice lacking AMPKβ1, which is highly
expressed in the liver and brain, were protected
against diet-induced obesity, insulin resistance
and hepatic steatosis, probably because of
reduced food intake (Ref. 132).
These studies show that the effects of AMPK on
glucose homeostasis are highly complex as a result
of isoform- and tissue-specific functions.
Simultaneous modulation of its activity in
different tissues can have opposing effects on
glucose homeostasis, which could complicate the
development of therapeutic approaches directly
targeting AMPK. However, isoform- and tissue-
specific targeting could also provide a basis for
highly specific and effective therapeutic
approaches in addition to metformin treatment.
Metformin and AMPK in clinical use
Metformin has been used in the clinic for several
decades for the treatment of insulin-resistant and
diabetic patients. The drug improves insulin
sensitivity, lowers blood glucose and
cholesterol levels without risk of acute
hypoglycaemia and weight gain, and reduces
the risk of diabetes-related complications such
as cardiovascular disease (Ref. 133). The notion
that metformin elicits its beneficial effects
mainly through the activation of AMPK is
further underlined by observations of mice
with abolished hepatic AMPK activity due to
hepatocyte-specific LKB1 deficiency (Ref. 134).
Metformin failed to lower blood glucose in
these mice, indicating that activation of AMPK
through LKB1 in the liver is required (Ref. 134).
Nevertheless, several AMPK-independent
effects of metformin have been reported
(Ref. 110). It was recently shown that
metformin can block gluconeogenesis in
isolated mouse hepatocytes independently of
LKB1 and AMPK (Ref. 135).The mechanism of
AMPK activation by metformin is still
controversial. One hypothesis is that metformin
activates AMPK indirectly by inhibiting
complex I of the respiratory chain, which
compromises cellular energy production and
increases the AMP/ATP ratio (Refs 136, 137).
However, metformin also activates AMPK in an
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adenine-nucleotide-independent manner
(Ref. 138). More recently, it was proposed that
metformin activates PKCζ, which
phosphorylates LKB1 at Ser428, resulting in
nuclear export of LKB1 and activation of
AMPK (Ref. 139). Metformin may mainly
activate AMPK in the liver, muscle and
vasculature, because cellular uptake of the drug
is dependent on transmembrane transporters
such as solute carrier family 22 (organic cation
transporter), member 1 (SLC22A1, OCT-1).
Whereas OCT-1-deficient mice indeed have a
diminished response to metformin, the role of
OCT-1 polymorphisms in diabetic patients is
controversial (Refs 140, 141).
Metformin is used at inconveniently high
doses, and its clinical use is restricted in
patients with renal or hepatic disease owing to
increased risk of lactic acidosis (Ref. 133).
Hence, direct activation of AMPK by other
means would be an attractive alternative in the
treatment of diabetic patients. The AMPK
activator A-769662 efficiently lowered blood
glucose and triglycerides and transiently
reduced body weight gain in mouse models of
genetically induced obesity and insulin
resistance (Ref. 142). In addition, treatment
with AICAR was shown to reduce blood
glucose levels in diabetic patients. One side
effect associated with the activation of AMPK
could be increased food intake because of its
role in the hypothalamus. However, treatment
with metformin reduces body weight in
patients by decreasing appetite and food intake
(Refs 143, 144). The underlying mechanisms
remain poorly understood (Refs 143, 144). A
transient reduction in food intake was reported
in obese mice, but not in lean mice treated with
A-769662, because this drug may not activate
AMPK in the brain (Ref. 142). By contrast,
increased food intake was observed in mice
treated with AICAR (Refs 131, 145). A-769662
and AICAR were also shown to have AMPK-
independent activity, and possible side effects
of long-term treatment have not been assessed
(Refs 146, 147).
Metformin is now also considered for use in
cancer therapy. Epidemiological studies have
assessed the association between obesity or
T2DM and cancer in large populations
(Refs 148, 149). Although intensively
investigated, the molecular mechanisms linking
cancer with obesity are still not fully
elucidated. Chronic hyperinsulinaemia has
been suggested to contribute to increased
tumour growth, because it may directly
activate insulin receptor on (pre-)neoplastic
cells or indirectly through promotion of
insulin-like growth factor 1 (IGF1) synthesis.
Both insulin and IGF1 enhance tumour growth
in xenograft models by increasing cell
proliferation and inhibiting apoptosis. There is
an ongoing debate as to whether the use of
insulin analogues in the treatment of obese and
diabetic patients could further increase the risk
of cancer. Whereas certain insulin analogues do
lead to tumour development in rats, their
effect in human patients remains controversial
(Refs 150, 151, 152). In line with the
amelioration of obesity and hyperinsulinemia
by metformin, observational data showed that
its use was associated with a reduced risk of
cancer (Refs 143, 153, 154). Additionally, it
might also inhibit tumor progression by
AMPK-mediated inhibition of mTORC1, and
possibly also by a Rac GTPase-dependent and
AMPK-independent mechanism (Ref. 155).
Combined cancer therapy with metformin and
drugs targeting the PI3K/AKT pathway might
result in the synergistic inhibition of mTORC1.
This strategy could also overcome impaired
glucose homeostasis resulting from PI3K/AKT
pathway inhibition.
Concluding remarks
The insulin signal transduction network and the
biochemical properties of its components have
been extensively studied. There is increasing
knowledge of how PI3K/AKT, MAPK and
AMPK signalling controls and how their failure
impairs glucose homeostasis. Moreover, studies
in transgenic mice have demonstrated that
specific modulation of protein kinase signalling
can effectively improve glucose homeostasis and
protect against obesity, acquired insulin resistance
and diabetes. However, very little translation into
clinical practice has taken place. Metabolically
relevant cellular functions such as glucose
transport, lipogenesis, glycogen synthesis and
gluconeogenesis are controlled by kinases that do
not act exclusively within the insulin signal
transduction network. It has emerged that all
signal transduction events within a cell are
interconnected and that mere description of the
network is not sufficient to define mechanisms
underlying both context and stimuli specificity.
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Hence, global modulation of kinase activity by, for
example deletion of PTEN and the use of mTOR
inhibitors might result in severe side effects such
as cancer and impaired metabolic control,
respectively. The development of safe kinase-
based therapies will probably remain elusive
until we understand how cells integrate
signalling information to implement context in
their respective intracellular signal transduction
network. In addition, the development of specific
inhibitors is complicated by high structural
similarities in the catalytic domains of different
protein kinases. Reduced specificity resulting in
the inhibition of multiple targets could be
beneficial in cancer therapy because it might
potentiate toxicity on cancer cells. Inhibitors used
for the treatment of metabolic syndrome should,
by contrast, be highly specific in order to
minimise side effects and allow long-term
treatment. Targeting kinases in their inactive
state, in which they show higher structural
diversity than in their active conformation, or
disrupting protein complexes of kinases was
suggested for the design of inhibitors with
increased specificity (Refs 156, 157, 158). Tissue-
specific targeting by using transmembrane
carriers or metabolic activation, as well as the
targeting of specific isoforms or effectors further
downstream, might provide a route to increased
specificity of drugs and minimal side effects.
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Figure
Figure 1. Simplified view of insulin-stimulated PI3K/AKT signalling and its substrates involved in cellular
metabolism.
Tables
Table 1. Overview of mouse models for AKT isoforms and downstream targets.
Table 2. Overview of mouse models for the role of Pten and Ptp1b in glucose homeostasis.
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6.2. Promiscuous affairs of PKB/AKT isoforms in metabolism. 
 
Schultze SM, Jensen J, Hemmings BA, Tschopp O, Niessen M.  
Published in Archives of Physiology and Biochemistry 2011; 117 (2): 70-77. 
 
Abstract 
The protein kinase B (PKB) family encompasses three isoforms; PKBα (AKT1), PKBβ (AKT2) 
and PKBγ (AKT3). PKBα and PKBβ but not PKBγ, are prominently expressed in classical 
insulin-sensitive tissues like liver, muscle and fat. Transgenic mice deficient for PKBα, PKBβ or 
PKBγ have been analysed to study the roles of PKB isoforms in metabolic regulation. Until 
recently, only loss of PKBβ was reported to result in metabolic disorders, especially insulin 
resistance, in humans and mice. However, a new study has shown that PKBα-deficient mice can 
show enhanced glucose tolerance accompanied by improved β-cell function and higher insulin 
sensitivity in adipocytes. These findings prompted us to review the relevant literature on the 
regulation of glucose metabolism by PKB isoforms in liver, skeletal muscle, adipocytes and 
pancreas. 
 
Abstract taken from (111). 
 
Introduction
The level of circulating glucose has to be adjusted to 
variations in food intake and energy demands, which 
is primarily regulated by the insulin/glucagon system 
in mammals. Insulin lowers blood glucose by increas-
ing uptake and deposition into muscle and adipose 
tissue as well as by decreasing its release from the liver. 
Glucagon mainly acts on hepatocytes where it opposes 
the action of insulin and stimulates release of glucose 
into circulation. Insulin signalling targets various cell 
types in the whole organism and, in addition to its role 
in metabolism, affects cellular processes such as pro-
tein synthesis, proliferation and survival. Therefore a 
complex network of molecular pathways is required to 
transduce insulin signalling into cell type-specific and 
context-dependent responses. Protein kinase B (PKB) 
has been shown to be a key element in the insulin sig-
nal transduction network.
The physiological and tissue-specific effects of the 
three PKB isoforms have been extensively studied in 
vitro but most comprehensively in transgenic mice. 
While Pkbα-/- and Pkbγ-/- mice show impaired foetal 
growth and brain development, respectively, glucose 
homeostasis was found unaffected in both models 
(Chen et al., 2001; Cho et al., 2001b; Easton et al., 
2005; Tschopp et al., 2005; Yang et al., 2003). In con-
trast, Pkbβ-/- mice are insulin resistant, mildly glucose-
intolerant and have less adipose tissue. Depending on 
strain and gender, these mice show either late loss of 
β-cells followed by development of diabetes and mild 
growth deficiency, or compensatory increase of β-cell 
mass without age-dependent progression into overt 
hyperglycaemia (Cho et al., 2001a; Garofalo et al., 
2003). These studies suggested that only PKBβ plays 
a role in regulation of energy homeostasis. This view 
was recently challenged by a new study (Buzzi et al., 
2010) that re-examined in parallel the metabolic phe-
notypes of three mouse strains deficient for Pkbα, β or 
γ, respectively. Here they confirmed that Pkbβ-/- mice 
are insulin resistant with compensatory increase of 
islet mass and that Pkbγ-/- mice show no metabolic 
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abstract
The protein kinase B (PKB) family encompasses three isoforms; PKBα (AKT1), PKBβ (AKT2) and PKBγ (AKT3). 
PKBα and PKBβ but not PKBγ, are prominently expressed in classical insulin-sensitive tissues like liver, muscle 
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sensitivity in adipocytes. These findings prompted us to review the relevant literature on the regulation of 
glucose metabolism by PKB isoforms in liver, skeletal muscle, adipocytes and pancreas.
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2  S. M. Schultze et al.
abnormalities. However, Pkbα-/- mice displayed 
improved insulin sensitivity, lower blood glucose and 
higher serum glucagon concentrations. These new 
findings prompted us to critically review the relevant 
literature on the metabolic role of PKB isoforms.
Protein Kinase B
The PKB serine/threonine protein kinase family 
consists of three evolutionary conserved isoforms: 
PKBα (AKT1), PKBβ (AKT2) and PKBγ (AKT3). PKB 
was first isolated from transforming murine leukae-
mia virus AKT-8 by Staal et al in 1977, characterized 
as an oncogene and named akt (Staal et al., 1977). 
Two human homologues of the viral akt gene were 
identified later on and termed akt1 and akt2. In 
1991, a human serine/threonine kinase was cloned, 
which was termed related to the A and C kinases 
(RAC) and subsequently renamed to PKBα/Akt1 
(Jones et al., 1991, reviewed in Brazil and Hemmings, 
2001). Since the identification of PKBα as a serine/
threonine kinase, almost 20 years ago, PKB isoforms 
were studied intensively and are now considered as 
major regulators of elementary cellular process, such 
as proliferation, survival, cell growth and energy 
metabolism (Bozulic et al., 2008; Contreras-Ferrat 
et al., 2010; Haga et al., 2005; Heron-Milhavet et al., 
2006). Consequently, PKB isoforms play pivotal 
roles in physiology and their deregulation engen-
ders diseases, such as cancer, neurodegeneration 
and metabolic disorders (Altomare and Testa, 2005; 
Zhao and Townsend, 2009). Remarkably, activation 
of PKB isoforms by gene amplification or mutations 
in upstream regulators frequently occurs in human 
cancers (Carpten et al., 2007). The molecular and 
cellular biology of PKB isoforms has been compre-
hensively reviewed (Brazil et al., 2002; Hanada et al., 
2004; Manning and Cantley, 2007) and is therefore 
discussed only briefly in this review.
PKBα, PKBβ and PKBγ are encoded by three distinct 
genes, which are located on different chromosomes. In 
contrast to many members of other kinase families, 
PKB isoforms share the same protein structure and are 
approximately 80% identical at the amino acid level. 
They carry a N-terminal pleckstrin homology (PH) 
domain, a catalytic domain and a C-terminal regula-
tory domain (Hanada et al., 2004). PKBα and PKBβ 
are ubiquitously expressed, whereas PKBγ expres-
sion is restricted to brain, testis, lung, fat, mammary 
glands and pancreatic islets (Buzzi et al., 2010; Yang 
et al., 2003). Low expression levels were also observed 
in skeletal muscle (Brozinick et al., 2003). Notably, 
expression of PKBα and PKBβ is prominent in clas-
sical insulin target tissues involved in the regulation 
of systemic energy homeostasis, such as liver, skeletal 
muscle and fat (Yang et al., 2003).
PKB isoforms are activated by growth factors 
and cytokines, including PDGF, VEGF, HGF, IGF-1, 
insulin, TNFα and IL-2 but also by environmental 
stresses, such as heat shock, hypoxia and oxidative 
stress (Zhuravleva et al., 2010). Regulation of PKB 
downstream of these stimuli generally depends on 
activation of phosphatidyl-inositol 3-kinase (PI3K) 
family members, which convert phosphatidy-
inositol di-phosphate (PIP2) to PIP3 at the plasma 
membrane. PKB isoforms bind to PIP3 via their PH 
domain, which facilitates their activation. PKB iso-
forms are phosphorylated and thereby activated by 
upstream kinases at two distinct phosphorylation-
sites. First, PDK1 phosphorylates PKB isoforms at the 
catalytic domain (Thr308 in PKBα, Thr309 in PKBβ 
and Thr305 in PKBγ) which results in basal kinase 
activity of approximately 10%. In a second step, PKB 
isoforms are phosphorylated by mTORC2, DNA-PK 
or ATM at the C-terminal regulatory domain (Ser473 
in PKBα, Ser474 in PKBβ and Ser472 in PKBγ), which 
is essential for full kinase activity. Activation of 
PKB isoforms is tightly counter-regulated by phos-
phatases, such as PTEN and SHIP2. These phos-
phatases inactivate PIP3 by dephosphorylation and 
thereby prevent plasma membrane translocation 
and activation of PKB isoforms (Bhaskar and Hay, 
2007; Brazil and Hemmings, 2001; Hanada et al., 
2004; Zhuravleva et al., 2010).
Activity of PKB isoforms is modulated by differ-
ent binding partners, such as TRAF6, HSP90, CTMP 
and TCL1 which affect protein stability, dynamics 
and duration of activation and rate of kinase activ-
ity, respectively (Brazil et al., 2002). Furthermore, 
recent studies show that activity of PKB isoforms 
is indirectly modulated by several microRNAs. For 
instance, miR320 was shown to down-regulate PI3K 
in adipocytes resulting in inhibition of PKB activation 
and insulin resistance (Ling et al., 2009). However, 
it remains to be determined if modulation of PKB 
activity by binding partners and microRNAs plays a 
role in insulin signalling and regulation of glucose 
homeostasis.
Upon activation, PKB isoforms are released from 
the plasma membrane and phosphorylate various 
substrates throughout the cell. PKB substrates can 
specifically regulate a single respective cellular proc-
ess (e.g. cell survival, Bad or caspase 9), or pleiotropi-
cally affect several cellular functions simultaneously, 
such as GSK3β and FoxO transcription factors which 
can control cell survival, proliferation but also energy 
metabolism (Manning and Cantley, 2007)
The different phenotypes of Pkbα-/-, Pkbβ-/- and 
Pkbγ-/- mice undoubtedly point to isoform-specific 
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functions. As the expression of PKB isoforms over-
laps in many organs, the different phenotypes can 
not solely be explained by divergent gene expression. 
There is an emerging number of studies describing 
 isoform-specific functions in cellular processes, such 
as PKBα in cancer cell migration (Chin and Toker, 
2010), PKBα in β-cell proliferation and PKBβ in glu-
cose uptake. Since PKB isoforms are structurally highly 
similar, including the kinase domain, it is unlikely 
that recognition of phosphorylation-motifs underlies 
substrate-specificity (Manning and Cantley, 2007). 
Therefore it is considered that substrate-specificity is 
controlled by cellular localization and specific bind-
ing partners. However, until today, functional differ-
ences of PKB isoforms at the cellular level are not yet 
fully characterized and the mechanisms determining 
substrate-specificity remain largely unknown.
Liver
The liver functions as a critical regulator of glucose 
homeostasis and the PI3K/PKB pathway co-ordinates 
hepatic glucose metabolism with the systemic meta-
bolic state. Out of the three PKB isoforms, only PKBα 
and PKBβ, but not PKBγ, are expressed in the liver. 
Studies using transgenic mice have shown, that PKBβ 
accounts for approximately 70% of total PKB protein 
in the liver and is therefore considered as the major 
isoform (Dummler et al., 2006). In hepatocytes, PKBα 
and PKBβ are both activated upon insulin stimulation 
in a PI3K-dependent manner (Taniguchi et al., 2006).
According to the current model, insulin suppresses 
hepatic glucose output in several ways, including 
inhibition of gluconeogensis and stimulation of 
glycogen synthesis, which are both dependent on 
PKB activity (Newgard, 2003). Gluconeogenesis is 
suppressed after phosphorylation/inhibition of the 
transcription factor FoxO1, an inducer of gluconeo-
genic genes pepck and g6pase (Taniguchi et al., 2006). 
In addition, PKB also induces glycogen synthesis by 
phosphorylating and inhibiting GSK3β (Lawrence 
and Roach, 1997). Although it was shown that PKBβ 
(He et al., 2010, Leavens et al., 2009) plays a critical 
role in these processes, the effects of endogenous 
PKBα remain unclear. Furthermore, it was proposed 
that hepatic de novo lipogenesis is mainly regulated 
by PKCλ/ζ, as expression of lipogenic genes, such as 
srebp-1c, is depended on PKCλ/ζ activity (Taniguchi 
et al., 2006). Even so, several studies show that PKBα 
and PKBβ promote hepatic de novo lipogenesis as 
well (He et al., 2010; Leavens et al., 2009; Ono et al., 
2003).
The role of PKB activity in hepatic metabolism 
and its effects on systemic energy homeostasis was 
studied in mice with liver-specific deletions of major 
regulatory subunits of PI3K (pik3r1Δli/pik3r2Δli) and 
PTEN (ptenΔli) (Horie et al., 2004; Stiles et al., 2004; 
Taniguchi et al., 2006). Insulin-stimulated activation 
of PKBα, PKBβ and PKCλ/ζ was almost completely 
abrogated in pik3r1Δli/pik3r2Δli mice. Concomitantly, 
insulin also failed to down-regulate hepatic gluco-
neogenesis and could no longer inhibit GSK3β and 
induce  expression of lipogenic genes. As a conse-
quence, pik3r1Δli/pik3r2Δli mice exhibited insulin 
resistance, hyperglycaemia, hyperinsulinaemia and 
were glucose intolerant (Taniguchi et al., 2006). 
Remarkably, expression of gluconeogenic genes, 
pepck and g6pase was efficiently blocked after over-
expression of constitutive active PKBα (myr-PKBα) 
whereas expression of lipogenic genes, srebp-1c, 
could only be restored by over-expression of consti-
tutive active PKCλ/ζ (Taniguchi et al., 2006). On the 
other hand, gluconeogenic genes were down regu-
lated and phosphorylation of GSK3β and lipogenesis 
were enhanced in liver of ptenΔli mice, most likely 
due to hyper-activated PKBα, PKBβ and PKCλ/ζ. As 
a result, ptenΔli mice were found to be hypoglycae-
mic, hypoinsulinaemic, showed increased glucose 
tolerance and, most strikingly, developed hepatic 
steatosis with all characteristics of human non-
alcoholic fatty liver disease (Horie et al., 2004; Stiles 
et al., 2004).
In recent studies the role PKBβ in hepatic lipid 
accumulation was examined using different mouse 
models of hepatic steatosis (He et al., 2010; Leavens 
et al., 2009). Remarkably, whole-body deletion of 
pkbβ in ptenΔli, leptin-deficient (lepob/ob) and mice on 
high-fat diet (HFD) as well as liver-specific deletion of 
pkbβ in lepob/ob and mice on HFD significantly reduced 
lipid accumulation in hepatocytes. PKBβ-deficiency 
reduced expression of lipogenic genes and de novo 
lipogenesis, indicating that PKBβ is required for lipid 
accumulation in hepatocytes.
Interestingly, pkbβ-deficiency had more pro-
nounced effects in wildtype controls compared to 
ptenΔli mice. Therefore, increased activation of PKBα, 
and possibly also of PKCλ/ζ, might compensate for 
loss of PKBβ in hepatocytes. Indeed ectopic expression 
of constitutively active PKBα (myr-PKBα) in the liver 
induced hypoglycaemia and hepatic steotosis, further 
supporting the notion for functional overlap between 
PKBα and PKBβ in hepatocytes (Ono et al., 2003). 
However, activation of PKB isoforms by myristilation 
is rather artificial, and might induce non-physiological 
functions.
Notably, hepatic lipid content, but not de novo lipo-
genesis or expression of lipogenic genes, were reduced 
in PKBβ −deficient mice fed a specific HFD (Surwit 
diet; Leavens et al., 2009). Moreover,  expression of 
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myr-PKBα upregulated srebp-1c in wildtype but 
not pik3r1Δli/pik3r2Δli mice and additionally pro-
moted accumulation of hepatic lipids independent 
of srebp-1c (Ono et al., 2003; Taniguchi et al., 2006). 
These observations suggest that PKBα and PKBβ 
regulate other processes in addition and that reduced 
lipogenesis could be a secondary effect dependent on 
PI3K/PKC.
Skeletal muscle
Skeletal muscle is a specialized tissue that makes 
movement possible by transforming chemical energy 
into mechanical force. In addition, skeletal muscle is 
also central to metabolic regulation and 70 to 90% of 
glucose disposal during a hyperinsulinaemic eugly-
caemic clamp occurs in this tissue (DeFronzo et al., 
1981). Glucose taken up is mainly incorporated into 
glycogen (Shulman et al., 1990) and the majority 
(≈80%) of carbohydrates stored in humans are found 
in skeletal muscle (Jensen and Lai, 2009).
It is the generally accepted view that insulin 
activates PKB via class 1A PI3K (Shepherd, 2005). 
Although this has not been conclusively shown in 
fully differentiated skeletal muscle, all available data 
support the view that PKB promotes insulin-stimu-
lated glucose uptake and glycogen synthase activation 
(Cleasby et al., 2007). As in adipose tissue, glucose 
uptake is increased in skeletal muscle by triggering 
translocation of GLUT4 from intracellular vesicles 
to the plasma membrane, which depends on well 
studied signalling events downstream of the insu-
lin receptor involving IRS, PKB and AS160. Skeletal 
muscle expresses all three PKB isoforms (Brozinick 
et al., 2003; Turinsky and Damrau-Abney, 1999) but 
only deletion of PKBβ causes insulin resistance and 
reduces insulin-stimulated glucose uptake (Cho et al., 
2001a; Garofalo et al., 2003), indicating that PKBβ is 
required for this process. However, since high concen-
trations of insulin could still increase glucose disposal 
into muscle lacking PKBβ other signalling compo-
nents might also be able to regulate GLUT4 transloca-
tion downstream of insulin. Indeed, over-expression 
of constitutively active PKBβ increases glucose uptake 
in L6 muscle cells (Hajduch et al., 1998) suggesting 
that PKBα and PKBβ can both regulate translocation 
of GLUT4 to the plasma membrane. This finding is in 
line with the observation that insulin can activate all 
three isoforms of PKB in skeletal muscle (Brennesvik 
et al., 2005; Brozinick et al., 2003). Isoform-specific 
function has been investigated in several studies. 
Ectopic expression of constitutively active PKBα or 
PKBβ in vivo in rat muscle fibres increased glycogen 
accumulation, but only expression of PKBβ increased 
basal glucose uptake (Cleasby et al., 2007). However, 
only PKBα increased glycogen synthase kinase-3beta 
(GSK3β) phosphorylation. Knockdown of PKBβ in 
fully differentiated muscle fibres by electrotransfer of 
short hairpin (sh)-RNAs decreased insulin-stimulated 
glucose uptake suggesting isoform-specificity of PKB 
in regulation of glucose metabolism (Cleasby et al., 
2007). Unfortunately, the role PKBα was not addressed 
in this study. Interestingly, Brozinick et al. (2003) 
found that insulin-stimulated PKBβ activation was 
reduced in insulin resistant muscles whereas insulin-
stimulated activation of PKBα and PKBγ occurred 
normally. Evidence for isoform-specific signalling 
was provided by Bouzakri et al. (2006). These authors 
could show that activation of PKBβ via IRS1 stimulates 
glucose uptake whereas IRS2-mediated activation of 
PKBα increases lipid synthesis.
Besides insulin, muscle contraction can also induce 
glucose uptake. Contraction-induced glucose trans-
port depends on increased translocation of GLUT4 
but the underlying mechanism depends on AMPK and 
not on PI3K. However, contraction can increase PKB 
phosphorylation and activity (Sakamoto et al., 2003; 
Whitehead et al., 2000), but contraction-mediated 
PKB phosphorylation remains below 10% of insulin-
stimulated PKB phosphorylation (Whitehead et al., 
2000). Contraction increases activity of all isoforms, 
but PKBα activation is most pronounced (Sakamoto 
et al., 2002). The notion that PKB does not mediate 
 contraction-stimulated glucose uptake is in line with 
the fact that the PI3K inhibitor wortmannin does 
not inhibit contraction-stimulated glucose uptake 
(Whitehead et al., 2000). Accordingly, contraction-
stimulated glucose transport is normal in skeletal 
muscle of PKBβ-deficient mice (Sakamoto et al., 2006). 
Interestingly, contraction can block insulin-stimulated 
class 1A PI3K activity without reducing insulin-stimu-
lated PKB activation (Whitehead et al., 2000) indicat-
ing, that PKB phosphorylation might occur without 
increase in class 1A PI3K activity. This observation 
highlights the need to clarify which isoform(s) of PI3K 
mediate insulin-stimulated glucose uptake in skeletal 
muscle.
Adipose tissue
Insulin induces phosphorylation of PKB in adipocytes. 
Like in muscle and liver, the level of phosphoryla-
tion/activation of PKB after insulin stimulation is 
often regarded as benchmark for insulin sensitivity. 
This consensus is based on observations, that insulin 
resistance in adipose tissue is in many cases associ-
ated with less insulin-induced phosphorylation of PKB 
and that increased or constitutive activation of PKB 
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can increase or mimic insulin action, respectively. 
Many lines of evidence suggest, that mainly PKBβ is 
required downstream of insulin in adipocytes. For 
example, transient down-regulation of PKBβ using 
siRNAs inhibits insulin-induced GLUT4 transloca-
tion to the plasma membrane of 3T3-L1 adipocytes 
whereas knockdown of PKBα did not result in any 
differences (Jiang et al., 2003; Katome et al., 2003). 
These findings are in line with the observation that 
Pkbβ-/- mice are insulin resistant whereas Pkbα-/- mice 
are normal or even more insulin sensitive (Buzzi et al., 
2010; Chen et al., 2001; Cho et al., 2001a, b; Garofalo 
et al., 2003; Yang et al., 2003). However, not all meta-
bolic functions regulated by insulin in adipocytes 
might be dependent on PKBβ alone, as described by 
Katome et al. (2003). These authors analysed 2-DG 
uptake and glycogen synthesis in 3T3-L1 adipocytes 
after down-regulation of PKBα, β or γ and found that 
PKBα and PKBβ contributed to insulin-stimulated 
glycogen synthesis to about the same extent while 
2-DG uptake only depended on PKBβ. Accordingly, 
insulin appears to stimulate the association of PKBβ 
with GLUT4-containing vesicles in rat adipocytes 
(Calera et al., 1998) and  over-expression of PKBβ, 
but not PKBα, rescues impaired glucose transport 
in PKBβ-deficient adipocytes (Bae et al., 2003). How 
isoform-specificity might be achieved in adipocytes 
was studied by Gonzales and McGraw (2009). These 
authors found that insulin activates both PKBα and 
PKBβ in adipocytes, but describe differential sub-
cellular distribution of these two isoforms upon 
stimulation. While basally adipocytes had similar 
levels of PKBα and PKBβ at the plasma membrane, 
a significantly greater fraction of PKBβ accumulated 
at the plasma membrane after stimulation with insu-
lin. The question if PKB plays a role in lipogenesis 
has received surprisingly little attention. However, 
Berggreen et al. (2009) recently described that inhi-
bition of PKB in 3T3-L1 adipocytes with an inhibitor 
called Akti reduced de novo and insulin-dependent 
lipid synthesis and that insulin failed to regulate the 
rate-limiting lipogenic enzyme acetyl-CoA carboxy-
lase (ACC) when PKB was inhibited. Specific roles for 
the different isoforms of PKB were not described in 
this study.
Interestingly, there is a small but noteworthy 
number of studies with conflicting results. For example, 
Kitamura et al. (1998) expressed a  dominant-negative 
PKB isoform (Akt-AA) in 3T3-L1 adipocytes. This iso-
form contains two alanines instead of the two regu-
lated phosphorylation sites (Thr308 and Ser473) and its 
expression reduced activation of PKB by about 80–95%. 
Expression of Akt-AA inhibited  insulin-dependent 
protein synthesis without affecting glucose transport 
indicating, that PKB might only be required for some 
but not all effects of insulin in adipocytes. Similarly, 
Guilherme and Czech (1998) presented evidence 
that the formation of IRS1/PI3K complexes and Akt/
PKB activation are insufficient to stimulate glucose 
transport in rat adipocytes. At least two more recent 
studies also describe that insulin-dependent activa-
tion of PKB does not necessarily correlate with insulin-
induced 2-DG transport (Hoehn et al., 2008; Xu et al., 
2010). Finally, Buzzi et al. (2010) found that primary 
adipocytes isolated from Pkbα-deficient mice show 
higher insulin-induced glucose incorporation than 
adipocytes from wild type littermates.
Pancreatic islets
To proper regulate blood glucose homeostasis islet 
mass and function has to be co-ordinated with meta-
bolic demand. Plasticity of islet mass is achieved by 
integration of a complex signal environment com-
prised of nutrients, hormones and cytokines that con-
trols the balance between apoptosis and cell growth/
proliferation (Maedler, 2008; Niessen, 2006). Because 
PKB is a global regulator of growth, proliferation and 
apoptosis, it has been implicated to play a major role 
in modulating plasticity of islet mass downstream of 
insulin receptor substrate 2 (IRS2) (Elghazi et al., 2007; 
Hennige et al., 2003; Kubota et al., 2000; Lingohr et al., 
2003; Mohanty et al., 2005; Park et al., 2006; Takamoto 
et al., 2008; Withers et al., 1998; Wrede et al., 2002). 
Yet, a number of studies addressing this issue yielded 
somewhat unexpected results. Pkbα-deficient mice 
show impaired placental development and foetal 
growth (Buzzi et al., 2010; Chen et al., 2001; Tuttle 
et al., 2001; Yang et al., 2003) but normal islet growth 
and function. pkbβ-deficient mice show impaired 
overall growth but display, dependent on strain 
and sex, even compensatory increase in β-cell mass 
(Buzzi et al., 2010; Cho et al., 2001a; Garofalo et al., 
2003). Finally, pkbγ-deficient mice display reduction 
in brain size without any distortions of islet func-
tion or mass (Buzzi et al., 2010; Easton et al., 2005; 
Tschopp et al., 2005). In another study β-cell-specific 
loss of function for PKB was induced by expression 
of a kinase-dead dominant-negative form of PKBα 
(rip-kdpkb), however, only defective insulin secretion 
but no reduction in islet size was observed (Bernal-
Mizrachi et al., 2004). Since the dominant-negative 
form antagonizes all three isoforms this latter finding 
makes compensation between isoforms an unlikely 
explanation for the normal islet phenotypes of PKB-
deficient mice. In contrast to the loss of function 
phenotype, ectopic expression of constitutively active 
PKBα under the control of the rat insulin promoter 
(rip)  (Bernal-Mizrachi et al., 2001; Tuttle et al., 2001) 
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resulted in hypertrophy and hyperplasia of islets. 
Such mice were hyperinsulinaemic and resistant 
to streptozotocin-induced diabetes. Taken together 
the results from these mouse models suggest that 
although none of the PKB isoforms is required for 
maintenance of islet mass, constitutive activation 
of at least PKBα is sufficient to increase islet size. In 
order to reconcile these observations it was proposed 
(Niessen, 2006) that maintenance and compensa-
tory expansion of islet mass (as observed in insulin 
resistance) do not depend on the same signal trans-
duction pathways downstream of IRS2. This model 
predicts that PKB is only required for expansion 
but not for maintenance of islet mass. Which of the 
three PKB isoforms is/are required to regulate islets 
mass was studied recently by Buzzi et al. (2010). This 
study shows that only PKBα, but not PKBβ or γ, is 
specifically activated downstream of IRS2 in β-cells. 
Furthermore, adenoviral over-expression of PKBα 
increased proliferation of β-cells while over-expres-
sion of the remaining two isoforms was ineffective, 
indicating that PKBα is in control of the regulation 
of β-cell mass.
Perspectives and conclusions
Insulin sensitivity manifests at the signalling level and 
at the level of cellular function. Since the insulin recep-
tor is present on many, if not all, mammalian cells 
the biological function of insulin is cell type-specific, 
and, within a given cell type, insulin often controls 
more than one cellular process. For example, insulin 
induces GLUT4-dependent transport and deposition 
of glucose into fat. It also inhibits lipolysis. The analy-
sis of any of these endpoints after stimulation with 
insulin allows unambiguous determination of how 
insulin sensitive the target cell is for the respective 
function. It has become common practice in the field 
to correlate insulin-induced cellular effects with intra-
cellular insulin signal transduction, however, insulin 
sensitivity at the signalling level is not easy to measure 
because the insulin receptor connects to an intricate 
and highly context-specific intra-cellular network of 
signalling molecules. In practice insulin-dependent 
activation of few protein kinases within this network 
is usually correlated with specific insulin-induced cel-
lular responses. PKB is regarded as most important 
mediator of metabolic insulin action and its activation 
is often monitored by using phospho-specific antibod-
ies in combination with Western blotting. However, 
as described in this review, insulin signalling might 
branch at the level of PKB isoforms to control differ-
ent aspects of metabolic regulation but in most of the 
cases, the possibility for non-redundant roles of PKB 
isoforms is not taken into consideration. Technically, 
due to high conservation of the amino-acid sequence 
surrounding the phosphorylated Ser and Thr residues 
in the three isoforms, none of the available phospho-
specific antibodies can be used to determine which 
isoform(s) is (are) activated without prior isoform-
specific immunoprecipitation. As more and more 
evidence for specific and possibly even opposing 
roles of PKB isoforms accumulates it appears justified 
to reconsider the appropriateness of detecting PKB 
phosphorylation to assess overall insulin sensitivity 
without consideration of the specific isoform.
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6.3. Liver Failure After Extended Hepatectomy in Mice Is Mediated by a p21-
Dependent Barrier to Liver Regeneration  
 
Lehmann K,  Tschuor C, Rickenbacher A,  Jang JH, Oberkofler CC, Tschopp O, Schultze SM, 
Raptis DA, Weber A, Graf R,  Humar B, Clavien PA.  
Published in Gastroenterology 2012; 143 (6): 1609–1619. 
 
Abstract 
Background & Aims: Extended liver resection leads to hepatic failure because of a small 
remnant liver volume. Excessive parenchymal damage has been proposed as the principal cause 
of this failure, but little is known about the contribution of a primary deficiency in liver 
regeneration. We developed a mouse model to assess the regenerative capacity of a critically 
small liver remnant. 
 
Methods: Extended (86%) hepatectomy (eHx) was modified to minimize collateral damage; 
effects were compared with those of standard (68%) partial hepatectomy (pHx) in mice. Markers 
of liver integrity and survival were evaluated after resection. Liver regeneration was assessed by 
weight gain, proliferative activity (analyses of Ki67, proliferating cell nuclear antigen, 
phosphorylated histone 3, mitosis, and ploidy), and regeneration-associated molecules. Knockout 
mice were used to study the role of p21. 
 
Results: Compared with pHx, survival of mice was reduced after eHx, and associated with 
cholestasis and impaired liver function. However, no significant differences in hepatocyte death, 
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sinusoidal injury, oxidative stress, or energy depletion were observed between mice after eHx or 
pHx. No defect in the initiation of hepatocyte proliferation was apparent. However, restoration of 
liver mass was delayed after eHx and associated with inadequate induction of Foxm1b and a 
p21-dependent delay in cell-cycle progression. In p21-/- mice, the cell cycle was restored, the 
gain in liver weight was accelerated, and survival improved after eHx. 
 
Conclusions: Significant parenchymal injury is not required for liver failure to develop after 
extended hepatectomy. Rather, liver dysfunction after eHx results from a transient, p21-
dependent block before hepatocyte division. Therefore, a deficiency in cell-cycle progression 
causes liver failure after extended hepatectomy and can be overcome by inhibition of p21. 
 
Abstract taken from (143). 
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6.4. Toll-like receptor 2-deficient mice are protected from insulin resistance 
and beta cell dysfunction induced by a high-fat diet 
 
Ehses JA, Meier DT, Wueest S, Rytka J, Boller S, Wielinga PY, Schraenen A, Lemaire K, 
Debray S, Van Lommel L, Pospisilik JA, Tschopp O, Schultze SM, Malipiero U, Esterbauer H, 
Ellingsgaard H, Rütti S, Schuit FC, Lutz TA, Böni-Schnetzler M, Konrad M, Donath MY.  
Published in Diabetologia 2010; 53 (8): 1795-1806.  
 
Abstract  
Aims/hypothesis: Inflammation contributes to both insulin resistance and pancreatic beta cell 
failure in human type 2 diabetes. Toll-like receptors (TLRs) are highly conserved pattern 
recognition receptors that coordinate the innate inflammatory response to numerous substances, 
including NEFAs. Here we investigated a potential contribution of TLR2 to the metabolic 
dysregulation induced by high-fat diet (HFD) feeding in mice. 
 
Methods: Male and female littermate Tlr2 +/+ and Tlr2 −/− mice were analysed with respect to 
glucose tolerance, insulin sensitivity, insulin secretion and energy metabolism on chow and 
HFD. Adipose, liver, muscle and islet pathology and inflammation were examined using 
molecular approaches. Macrophages and dendritic immune cells, in addition to pancreatic islets 
were investigated in vitro with respect to NEFA-induced cytokine production. 
 
Results: While not showing any differences in glucose homeostasis on chow diet, both male and 
female Tlr2 −/− mice were protected from the adverse effects of HFD compared with Tlr2 +/+ 
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littermate controls. Female Tlr2 −/− mice showed pronounced improvements in glucose tolerance, 
insulin sensitivity, and insulin secretion following 20 weeks of HFD feeding. These effects were 
associated with an increased capacity of Tlr2 −/− mice to preferentially burn fat, combined with 
reduced tissue inflammation. Bone-marrow-derived dendritic cells and pancreatic islets from 
Tlr2 −/− mice did not increase IL-1β expression in response to a NEFA mixture, whereas Tlr2 +/+ 
control tissues did. 
 
Conclusion/interpretation: These data suggest that TLR2 is a molecular link between increased 
dietary lipid intake and the regulation of glucose homeostasis, via regulation of energy substrate 
utilisation and tissue inflammation. 
 
Abstract taken from (56). 
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